<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Drugs</journal-id><journal-title-group><journal-title>Drugs</journal-title></journal-title-group><issn pub-type="ppub">0012-6667</issn><issn pub-type="epub">1179-1950</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25344022</article-id><article-id pub-id-type="pmc">4224737</article-id><article-id pub-id-type="publisher-id">305</article-id><article-id pub-id-type="doi">10.1007/s40265-014-0305-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Leading Article</subject></subj-group></article-categories><title-group><article-title>Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Shih</surname><given-names>Kent</given-names></name><address><phone>(615) 385-3571</phone><email>kshih@tnonc.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Arkenau</surname><given-names>Hendrik-Tobias</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Infante</surname><given-names>Jeffrey R.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN 37203 USA </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>10</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>10</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>74</volume><issue>17</issue><fpage>1993</fpage><lpage>2013</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><p>Immune responses are tightly regulated via signaling through numerous co-stimulatory and co-inhibitory molecules. Exploitation of these immune checkpoint pathways is one of the mechanisms by which tumors evade and/or escape the immune system. A growing understanding of the biology of immune checkpoints and tumor immunology has led to the development of monoclonal antibodies designed to target co-stimulatory and co-inhibitory molecules in order to re-engage the immune system and restore antitumor immune responses. Anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies were among the first to be tested in the clinic, and ipilimumab was the first immune checkpoint inhibitor approved for an anticancer indication. Agents targeting the programmed death 1 (PD-1) pathway, either PD-1 or one of its ligands, programmed death ligand 1, are in active clinical development for numerous cancers, including advanced melanoma and lung cancer. Understanding the different mechanisms of action, safety profiles, and response patterns associated with inhibition of the CTLA-4 and PD-1 pathways may improve patient management as these therapies are moved in to the clinical practice setting and may also provide a rationale for combination therapy with different inhibitors. Additional immune checkpoint molecules with therapeutic potential, including lymphocyte activation gene-3 and glucocorticoid-induced tumor necrosis factor receptor-related gene, also have inhibitors in early stages of clinical development. Clinical responses and safety data reported to date on immune checkpoint inhibitors suggest these agents may have the potential to markedly improve outcomes for patients with cancer.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d30e177"><title>Key Points</title><p><table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Immune checkpoint inhibitors are designed to interrupt inhibitory immune signals and restore immune responses against tumors.</td></tr><tr><td align="left">Numerous immune checkpoint inhibitors are in advanced stages of development and show activity across multiple tumor types, including advanced melanoma and advanced non-small-cell lung cancer.</td></tr><tr><td align="left">Understanding the mechanism-associated adverse events and response patterns is important to the management of patients as these drugs are moved into the clinical practice setting.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1" sec-type="intro"><title>Introduction</title><p>Rudolph Virchow may have been one of the first physicians in modern times to observe the link between the immune system and malignancy in what he termed &#x0201c;lymphoreticular infiltrates&#x0201d;. These infiltrates were leukocytes surrounding malignant tumors, and he hypothesized that proinflammatory states might induce normal tissues to become malignant [<xref ref-type="bibr" rid="CR1">1</xref>]. Since then, we have learned a great deal about how the immune system responds and reacts to tumors, which tumor-specific antigens are recognized as foreign, and how immune responses can be manipulated and harnessed to enhance tumor cell killing.</p><p>Recently, it has been recognized that, on its own, tumor peptide presentation by major histocompatibility complex (MHC) to T-cell receptors is inadequate for successful T-cell activation and immune destruction of cancer cells. Co-regulatory signals, either inhibitory or stimulatory, are also required [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. T cells play a critical role in cell-mediated tumor immunity, and do so through an intricate counterbalance of co-stimulatory and co-inhibitory cell-to-cell signals between various components of the immune system. This system of checks and balances is necessary not only to allow a powerful destructive response against both pathogens and malignancies, but also to prevent immune responses from being generated against normal tissues. Critical &#x02018;checkpoints&#x02019; control and fine-tune the immune system through regulation of this complex network of co-stimulatory and co-inhibitory signaling [<xref ref-type="bibr" rid="CR3">3</xref>]. In this paper, we review some of the important immune checkpoint molecules elucidated to date, as well as efforts to block these molecules in order to shift the balance towards antitumor immunity. We also describe some of the complexities and challenges encountered using these checkpoint inhibitors in the clinic.</p></sec><sec id="Sec2"><title>Cytotoxic T-Lymphocyte-Associated Antigen (CTLA)-4</title><sec id="Sec3"><title>Background</title><p>More than 40&#x000a0;years of research has led to the development of a two-signal theory of T-cell activation: antigenic stimulation of the T-cell receptor (TCR) (signal 1) together with co-stimulation by other molecules on the cell surface (signal 2) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. One of the key co-stimulatory mechanisms involves the interaction of CD28 on the surface of the T cell with B7 molecules CD80 or CD86 on antigen-presenting cells. CTLA-4, a transmembrane glycoprotein with considerable homology to CD28, binds to the same B7 ligands, as such (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Upon TCR stimulation by antigens, T cells express CTLA-4, which can bind B7 molecules; however, unlike CD28, CTLA-4 inhibits T-cell responses and is important for maintenance of immune tolerance. Expression of CTLA-4 raises the activation threshold and attenuates clonal expansion; thus, a productive T-cell response ensues only upon a net co-stimulatory signal.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>T-cell activation and immune checkpoint pathways. T-cell activation requires two signals: (1) presentation of antigenic peptides by MHC to the TCR and (2) co-stimulation, typically via CD28:CD80 or CD28:CD86 ligation. Immune checkpoint pathways comprising receptors on T cells and ligands on antigen-presenting cells and/or tumors fine-tune immune responses via T-cell activation or inhibition. <italic>CTLA-4</italic> cytotoxic T-lymphocyte-associated antigen 4, <italic>GAL9</italic> galectin-9, <italic>GITR</italic> glucocorticoid-induced TNF receptor-related gene, <italic>GITRL</italic> glucocorticoid-induced TNF receptor-related gene ligand, <italic>LAG-3</italic> lymphocyte activation gene-3, <italic>MHC</italic> major histocompatibility complex, <italic>PD-1</italic> programmed death-1, <italic>PD-L1</italic> programmed death ligand 1, <italic>PD-L2</italic> programmed death ligand 2, <italic>TCR</italic> T-cell receptor, <italic>TIM3</italic> T-cell immunoglobulin and mucin domain 3, <italic>TNF</italic> tumor necrosis factor</p></caption><graphic xlink:href="40265_2014_305_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Efficacy of CTLA-4 Inhibitors</title><sec id="Sec5"><title>Ipilimumab</title><p>Ipilimumab, one of the best-studied monoclonal antibodies targeting CTLA-4 (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]), has been evaluated in a clinical trial program of more than 2,000 patients with a variety of solid tumors [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Ipilimumab (Yervoy<sup>&#x000ae;</sup>), administered every 3&#x000a0;weeks for four doses, gained US FDA approval in 2011 for the treatment of unresectable or metastatic melanoma, based on data from two phase III randomized trials showing improvement on median overall survival (OS) over control arms in patients with melanoma [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. One of the pivotal phase III trials evaluated ipilimumab with or without gp100 vaccine in previously treated patients with advanced melanoma. Although the best overall response rates were modest, 10.9&#x000a0;% in the ipilimumab-alone group and 5.7&#x000a0;% in the ipilimumab plus gp100 vaccine group, some patients in both groups maintained an objective response for at least 2&#x000a0;years [<xref ref-type="bibr" rid="CR4">4</xref>]. In this trial, the 3-year OS rate for ipilimumab monotherapy was 20&#x000a0;% [<xref ref-type="bibr" rid="CR4">4</xref>], which compares favorably with the 3-year OS rate of 17&#x000a0;% for historical control patients receiving standard of care chemotherapy in a separate clinical trial [<xref ref-type="bibr" rid="CR21">21</xref>] (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]). The other pivotal phase III trial was conducted in treatment-na&#x000ef;ve patients with metastatic melanoma and compared ipilimumab plus dacarbazine versus dacarbazine plus placebo [<xref ref-type="bibr" rid="CR5">5</xref>]. Although the dose and schedule were slightly different, the rate of best overall response was 15&#x000a0;% in the ipilimumab plus dacarbazine group versus 10&#x000a0;% for the dacarbazine plus placebo group, while the median duration of response was 19.3 versus 8.1&#x000a0;months for the dacarbazine plus placebo group. Responses lasting at least 2&#x000a0;years were observed in both treatment groups. The 3-year survival rate with ipilimumab plus dacarbazine was significantly higher than dacarbazine plus placebo: 20.8 versus 12.2&#x000a0;% (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Immune checkpoint inhibitors in clinical development [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Name</th><th align="left">Company</th><th align="left">Description of agent</th></tr></thead><tbody><tr><td align="left">Ipilimumab [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]</td><td align="left">Bristol-Myers Squibb</td><td align="left">Human IgG1 mAb against CTLA-4</td></tr><tr><td align="left">Tremelimumab [<xref ref-type="bibr" rid="CR6">6</xref>]</td><td align="left">MedImmune/AstraZeneca</td><td align="left">Human IgG2 mAb against CTLA-4</td></tr><tr><td align="left">Pembrolizumab (MK-3475) [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td align="left">Merck</td><td align="left">Humanized IgG4 mAb against PD-1</td></tr><tr><td align="left">Nivolumab (BMS-936558) [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td align="left">Bristol-Myers Squibb</td><td align="left">Human IgG4 mAb against PD-1</td></tr><tr><td align="left">Pidilizumab (CT-011) [<xref ref-type="bibr" rid="CR9">9</xref>]</td><td align="left">CureTech</td><td align="left">Humanized IgG1 mAb against PD-1</td></tr><tr><td align="left">AMP-224 [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td align="left">Amplimmune; GlaxoSmithKline</td><td align="left">PD-L2-IgG recombinant fusion protein</td></tr><tr><td align="left">MPDL3280A [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">Genentech/Roche</td><td align="left">Human IgG mAb against PD-L1</td></tr><tr><td align="left">BMS-936559 [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">Bristol-Myers Squibb</td><td align="left">Human IgG4 mAb against PD-L1</td></tr><tr><td align="left">MEDI4736 [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">MedImmune/AstraZeneca</td><td align="left">Human mAb against PD-L1</td></tr><tr><td align="left">IMP321 [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">Immutep</td><td align="left">Soluble LAG-3 Ig fusion protein and MHC class II agonist</td></tr><tr><td align="left">TRX518 [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">GITR, Inc</td><td align="left">Humanized mAb against GITR</td></tr></tbody></table><table-wrap-foot><p>
<italic>CTLA-4</italic> cytotoxic T-lymphocyte-associated antigen 4, <italic>GITR</italic> glucocorticoid-induced tumor necrosis factor receptor-related gene, <italic>IgG</italic> immunoglobulin G, <italic>LAG-3</italic> lymphocyte activation gene-3, <italic>mAb</italic> monoclonal antibody, <italic>MHC</italic> major histocompatibility complex, <italic>PD-1</italic> programmed death 1, <italic>PD-L1</italic> programmed death ligand 1, <italic>PD-L2</italic> programmed death ligand 2</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Preliminary efficacy data with immune checkpoint inhibitors or controls from individual (not head-to-head) trials<sup>a</sup> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Advanced tumor setting</th><th align="left">Agent or control</th><th align="left">Median PFS</th><th align="left">Median OS</th><th align="left">Survival rate</th><th align="left">Reference(s)</th></tr></thead><tbody><tr><td align="left" rowspan="7">Melanoma</td><td align="left">CTX (CTX-na&#x000ef;ve pts)</td><td align="left">ND</td><td align="left">9.1&#x02013;10.7&#x000a0;months</td><td align="left">1-year: 36&#x000a0;%<break/>3-year: 12&#x02013;17&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left">Ipilimumab</td><td align="left">2.9&#x000a0;months</td><td align="left">10.1&#x000a0;months</td><td align="left">3-year: &#x02248;20&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td align="left">Tremelimumab</td><td align="left">ND</td><td align="left">12.6&#x000a0;months</td><td align="left">3-year: 21&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left">Pembrolizumab</td><td align="left">5.5&#x000a0;months</td><td align="left">NR</td><td align="left">1-year: 69&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR7">7</xref>]</td></tr><tr><td align="left">Nivolumab</td><td align="left">3.7&#x000a0;months</td><td align="left">17.3&#x000a0;months</td><td align="left">1-year: 63&#x000a0;%<break/>3-year: 41&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left">Pidilizumab</td><td align="left">1.9&#x000a0;months</td><td align="left">ND</td><td align="left">1-year: 65&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td align="left">Nivolumab plus ipilimumab</td><td align="left">27&#x000a0;weeks</td><td align="left">40&#x000a0;months</td><td align="left">1-year: 85&#x000a0;%<break/>2-year: 79&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR24">24</xref>]</td></tr><tr><td align="left" rowspan="4">NSCLC</td><td align="left">CTX (CTX-na&#x000ef;ve pts)</td><td align="left">4.2&#x000a0;months</td><td align="left">8.3&#x000a0;months</td><td align="left">1-year: 39&#x000a0;%<break/>2-year: 18&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left">Pembrolizumab</td><td align="left">10&#x02013;27 weeks<sup>b</sup>
</td><td align="left">51&#x000a0;weeks</td><td align="left">ND</td><td align="left">[<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left">Nivolumab (previously-treated pts)</td><td align="left">2.3&#x000a0;months</td><td align="left">9.9&#x000a0;months</td><td align="left">1-year: 42&#x000a0;%<break/>3-year: 24&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left">Nivolumab (CTX-na&#x000ef;ve pts)</td><td align="left">36.1&#x000a0;weeks</td><td align="left">NR</td><td align="left">1-year: 75&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td align="left" rowspan="2">RCC</td><td align="left">Sorafenib</td><td align="left">3.6&#x02013;5.7&#x000a0;months</td><td align="left">11.0&#x02013;19.2&#x000a0;months</td><td align="left">3-year: &#x02248;25&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td align="left">Nivolumab</td><td align="left">2.7&#x02013;4.2<sup>c</sup>&#x000a0;months</td><td align="left">18.2&#x02013;24.7<sup>c</sup>&#x000a0;months</td><td align="left">2.5-year: &#x02248;35&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td align="left" rowspan="2">CRPC</td><td align="left">Placebo</td><td align="left">3.1&#x000a0;months</td><td align="left">10.0&#x000a0;months</td><td align="left">1-year: 40&#x000a0;%<break/>2-year: 15&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td align="left">Ipilimumab</td><td align="left">4.0&#x000a0;months</td><td align="left">11.2&#x000a0;months</td><td align="left">1-year: 47&#x000a0;%<break/>2-year: 26&#x000a0;%</td><td align="left">[<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr></tbody></table><table-wrap-foot><p>
<italic>CRPC</italic> castration-resistant prostate cancer, <italic>CTX</italic> chemotherapy, <italic>ND</italic> no data, <italic>NR</italic> not reached, <italic>NSCLC</italic> non-small-cell lung cancer, <italic>OS</italic> overall survival, <italic>PFS</italic> progression-free survival, <italic>pts</italic> patients, <italic>RCC</italic> renal cell carcinoma</p><p>
<sup>a</sup>Important: data are not from head-to-head trials, and the trials differ by patient characteristics, patient numbers, and length of follow-up, therefore direct comparisons across trials and agents have limited validity; trials in tumor types with PFS and OS data were included</p><p>
<sup>b</sup>Based on differing studies and data-cuts</p><p>
<sup>c</sup>Dose-dependent</p></table-wrap-foot></table-wrap></p><p>Ipilimumab was evaluated as adjuvant therapy following complete resection of stage III melanoma in a phase III trial in patients at high risk of recurrence [<xref ref-type="bibr" rid="CR34">34</xref>]. Patients receiving ipilimumab had a significantly increased median OS as compared with patients receiving placebo: 26.1 versus 17.1&#x000a0;months (<italic>P</italic>&#x000a0;=&#x000a0;0.0013). The 3-year rates of recurrence-free survival were 47&#x000a0;% for ipilimumab and 35&#x000a0;% for placebo.</p><p>Preclinical studies suggest that chemotherapy can induce the release of tumor-specific antigens, thereby initiating T-cell activation and sensitizing tumor cells to T-cell-mediated killing [<xref ref-type="bibr" rid="CR35">35</xref>]. These observations provided the rationale for combining immunotherapy with cytotoxic agents to improve responses in patients with melanoma, and also led to the initiation of clinical trials evaluating ipilimumab with chemotherapy in lung cancer. A phase II, randomized study provided evidence that sequential ipilimumab is more effective than concurrent ipilimumab when administered with paclitaxel/carboplatin in chemotherapy-na&#x000ef;ve stage IIIB/IV patients with non-small-cell lung cancer (NSCLC). The median OS with sequential ipilimumab, concurrent ipilimumab, and the control regimen was 12.2, 9.7, and 8.3&#x000a0;months, respectively. In this trial, patients with squamous histology exhibited better outcomes (median immune-related progression-free survival [irPFS] and OS) with sequential ipilimumab dosing than did patients with non-squamous histology [<xref ref-type="bibr" rid="CR18">18</xref>]. Based on these findings, a phase III trial evaluating OS in patients with squamous NSCLC receiving sequential ipilimumab after chemotherapy was initiated (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR16">16</xref>]).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Ongoing phase II and III clinical trials of immune checkpoint inhibitors [<xref ref-type="bibr" rid="CR16">16</xref>]<sup>a</sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Target<break/>Treatment approach<break/>Tumor type</th><th align="left">Trial phase</th><th align="left">Treatment setting</th><th align="left">Trial stage (no. patients)</th><th align="left">Clinical endpoints</th><th align="left">Estimated primary/final completion date</th><th align="left">Trial identifier</th></tr></thead><tbody><tr><td align="left" colspan="7">
<bold>CTLA-4</bold>
</td></tr><tr><td align="left" colspan="7">
<italic>Ipilimumab</italic>
<sup>b</sup>
</td></tr><tr><td align="left" colspan="7">Lung cancer</td></tr><tr><td align="left">&#x000a0;Ipilimumab&#x000a0;+&#x000a0;etoposide/platinum vs. etoposide/platinum</td><td align="left">III</td><td align="left">Extensive-disease SCLC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;1,100)</td><td align="left">Primary: OS<break/>Secondary: OS, irPFS, BORR, DOR</td><td align="left">Nov 2015/Mar 2017</td><td align="left">NCT01450761</td></tr><tr><td align="left">&#x000a0;Ipilimumab&#x000a0;+&#x000a0;paclitaxel/carboplatin vs. paclitaxel/carboplatin</td><td align="left">III</td><td align="left">Stage IV/recurrent squamous NSCLC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;920)</td><td align="left">Primary: OS<break/>Secondary: OS, PFS, BORR</td><td align="left">Apr 2015/Dec 2016</td><td align="left">NCT01285609</td></tr><tr><td align="left" colspan="7">Melanoma</td></tr><tr><td align="left">&#x000a0;Ipilimumab</td><td align="left">I/II</td><td align="left">Uveal melanoma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;141)</td><td align="left">Primary: MTD<break/>Secondary: OS</td><td align="left">Nov 2017</td><td align="left">NCT01585194</td></tr><tr><td align="left">&#x000a0;Ipilimumab&#x000a0;+&#x000a0;temozolomide</td><td align="left">II</td><td align="left">Metastatic melanoma</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;64)</td><td align="left">Primary: 6-month PFS</td><td align="left">May 2015</td><td align="left">NCT01119508</td></tr><tr><td align="left">&#x000a0;Ipilimumab vs. chemotherapy (retreatment)</td><td align="left">II</td><td align="left">Advanced melanoma with progression after initial disease control with ipilimumab</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;138)</td><td align="left">Primary: OS<break/>Secondary: DCR, BORR, QOL</td><td align="left">Jul 2016</td><td align="left">NCT01709162</td></tr><tr><td align="left">&#x000a0;Ipilimumab 3&#x000a0;mg/kg vs. 10&#x000a0;mg/kg</td><td align="left">III</td><td align="left">Unresectable or metastatic melanoma</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;700)</td><td align="left">Primary: OS<break/>Secondary: PFS, BORR, DCR, DOR, DSD</td><td align="left">Sep 2015/Dec 2016</td><td align="left">NCT01515189</td></tr><tr><td align="left">&#x000a0;Ipilimumab vs. placebo</td><td align="left">III</td><td align="left">High-risk stage III melanoma after surgical removal</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;950)</td><td align="left">Primary: RFS<break/>Secondary: OS, distant metastases-free survival, safety, QOL</td><td align="left">July 2013/April 2015</td><td align="left">NCT00636168</td></tr><tr><td align="left">&#x000a0;Ipilimumab vs. nivolumab vs. ipilimumab&#x000a0;+&#x000a0;nivolumab</td><td align="left">III</td><td align="left">Previously untreated advanced melanoma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;915)</td><td align="left">Primary: OS<break/>Secondary: PFS, ORR, PD-L1 biomarker, QOL</td><td align="left">Oct 2016/Oct 2017</td><td align="left">NCT01844505</td></tr><tr><td align="left">&#x000a0;Ipilimumab vs. high-dose IFN-&#x003b1;-2b</td><td align="left">III</td><td align="left">High-risk stage III or IV melanoma after surgical removal</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;1,500)</td><td align="left">Primary: Recurrence-free survival, OS<break/>Secondary: Safety, QOL</td><td align="left">May 2018</td><td align="left">NCT01274338</td></tr><tr><td align="left" colspan="6">Prostate cancer</td><td align="left"/></tr><tr><td align="left">&#x000a0;Ipilimumab + sipuleucel-T</td><td align="left">II</td><td align="left">Progressive metastatic prostate cancer</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;66)</td><td align="left">Primary: Safety, immune responses<break/>Secondary: PSA response, clinical response, immune markers</td><td align="left">Aug 2014/Aug 2015</td><td align="left">NCT01804465</td></tr><tr><td align="left">&#x000a0;Ipilimumab vs. placebo</td><td align="left">III</td><td align="left">Metastatic prostate cancer</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;600)</td><td align="left">Primary: OS<break/>Secondary: PFS, time to pain progression, time to subsequent non-hormonal systemic therapy, safety</td><td align="left">Jan 2015/Nov 2015</td><td align="left">NCT01057810</td></tr><tr><td align="left" colspan="7">Gastric cancer</td></tr><tr><td align="left">&#x000a0;Ipilimumab vs. standard of care</td><td align="left">II</td><td align="left">Unresectable or metastatic gastric and gastroesophageal cancer</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;114)</td><td align="left">Primary: irPFS<break/>Secondary: PFS, OS, irBORR</td><td align="left">Jul 2014/Mar 2015</td><td align="left">NCT01585987</td></tr><tr><td align="left">
<italic>Tremelimumab</italic>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Mesothelioma</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Tremelimumab vs. placebo</td><td align="left">II</td><td align="left">Unresectable malignant mesothelioma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;180)</td><td align="left">Primary: OS<break/>Secondary: DCR, PFS, ORR, DOR, safety, QOL, PK</td><td align="left">Jun 2015</td><td align="left">NCT01843374</td></tr><tr><td align="left">
<bold>PD-1</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">
<italic>Pembrolizumab</italic> (<italic>MK-3475</italic>)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Lung cancer</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Pembrolizumab vs. docetaxel</td><td align="left">II/III</td><td align="left">Previously treated PD-L1-positive NSCLC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;920)</td><td align="left">Primary: OS, PFS, safety<break/>Secondary: ORR, DOR</td><td align="left">Sep 2015/Jan 2020</td><td align="left">NCT01905657</td></tr><tr><td align="left">Melanoma</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Pembrolizumab vs. chemotherapy<sup>c</sup>
</td><td align="left">II</td><td align="left">Advanced melanoma with progression after prior therapy</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;510)</td><td align="left">Primary: PFS, OS<break/>Secondary: ORR, DOR</td><td align="left">Mar 2015/Jan 2016</td><td align="left">NCT01704287</td></tr><tr><td align="left">&#x000a0;Pembrolizumab vs. ipilimumab</td><td align="left">III</td><td align="left">Unresectable or metastatic melanoma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;645)</td><td align="left">Primary: PFS, OS<break/>Secondary: ORR</td><td align="left">Jul 2014/Mar 2016</td><td align="left">NCT01866319</td></tr><tr><td align="left">Melanoma or NSCLC with untreated brain metastases</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Pembrolizumab</td><td align="left">II</td><td align="left">Melanoma or NSCLC with untreated brain metastases</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;64)</td><td align="left">Primary: Response<break/>Secondary: Brain metastases response</td><td align="left">Dec 2018/Mar 2018</td><td align="left">NCT02085070</td></tr><tr><td align="left">Colon cancer</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Pembrolizumab</td><td align="left">II</td><td align="left">Colon cancer</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;71)</td><td align="left">Primary: irPFS, irOR<break/>Secondary: OS, irPFS, PFS, BORR, DCR, safety, biomarkers</td><td align="left">Jun 2017</td><td align="left">NCT01876511</td></tr><tr><td align="left">
<italic>Nivolumab</italic>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Lung cancer</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Nivolumab</td><td align="left">II</td><td align="left">Advanced or metastatic squamous cell NSCLC with &#x02265;2 prior systemic regimens</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;100)</td><td align="left">Primary: IRC-assessed ORR<break/>Secondary: Investigator-assessed ORR</td><td align="left">Feb 2014/Feb 2015</td><td align="left">NCT01721759</td></tr><tr><td align="left">&#x000a0;Nivolumab&#x000a0;+&#x000a0;epigenetic priming</td><td align="left">II</td><td align="left">Recurrent metastatic NSCLC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;120)</td><td align="left">Primary: Tumor response<break/>Secondary: PFS, TTP, OS, safety</td><td align="left">Jan 2015/Aug 2015</td><td align="left">NCT01928576</td></tr><tr><td align="left">&#x000a0;Nivolumab vs. docetaxel</td><td align="left">III</td><td align="left">Previously treated advanced or metastatic squamous cell NSCLC</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;264)</td><td align="left">Primary: IRC-assessed ORR, OS<break/>Secondary: IRC-assessed PFS, PD-L1 biomarker, DOR, TTR, QOL</td><td align="left">Aug 2014/Aug 2015</td><td align="left">NCT01642004</td></tr><tr><td align="left">&#x000a0;Nivolumab vs. docetaxel</td><td align="left">III</td><td align="left">Previously treated advanced or metastatic non-squamous cell NSCLC</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;574)</td><td align="left">Primary: OS<break/>Secondary: ORR, PFS, PD-L1 biomarker, DRSPR</td><td align="left">Nov 2014/Nov 2015</td><td align="left">NCT01673867</td></tr><tr><td align="left">Melanoma</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Nivolumab&#x000a0;+&#x000a0;ipilimumab vs. ipilimumab</td><td align="left">II</td><td align="left">Previously untreated, unresectable or metastatic melanoma</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;150)</td><td align="left">Primary: ORR<break/>Secondary: PFS, ORR and PFS in BRAF mutant patients, QOL</td><td align="left">Jul 2014/May 2015</td><td align="left">NCT01927419</td></tr><tr><td align="left">&#x000a0;Nivolumab&#x000a0;+&#x000a0;ipilimumab</td><td align="left">II</td><td align="left">Advanced or metastatic melanoma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;100)</td><td align="left">Primary: Safety<break/>Secondary: ORR, PR</td><td align="left">Aug 2014/Jan 2019</td><td align="left">NCT01783938</td></tr><tr><td align="left">&#x000a0;Nivolumab vs. dacarbazine or carboplatin/paclitaxel</td><td align="left">III</td><td align="left">Advanced melanoma with progression after ipilimumab</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;390)</td><td align="left">Primary: ORR, OS<break/>Secondary: PFS, PD-L1 biomarker, QOL</td><td align="left">May 2015/Jan 2016</td><td align="left">NCT01721746</td></tr><tr><td align="left">&#x000a0;Nivolumab vs. dacarbazine</td><td align="left">III</td><td align="left">Previously untreated unresectable or metastatic melanoma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;410)</td><td align="left">Primary: OS<break/>Secondary: PFS, ORR, PD-L1 biomarker, QOL</td><td align="left">Sep 2015/Nov 2015</td><td align="left">NCT01721772</td></tr><tr><td align="left">&#x000a0;Nivolumab or nivolumab&#x000a0;+&#x000a0;ipilimumab vs. ipilimumab</td><td align="left">III</td><td align="left">Previously untreated unresectable or metastatic melanoma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;915)</td><td align="left">Primary: OS<break/>Secondary: PFS, ORR, PD-L1 biomarker, QOL</td><td align="left">Oct 2016/Oct 2017</td><td align="left">NCT01844505</td></tr><tr><td align="left">RCC</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Nivolumab</td><td align="left">II</td><td align="left">Advanced or metastatic clear-cell RCC</td><td align="left">Ongoing (<italic>n</italic>&#x000a0;=&#x000a0;150)</td><td align="left">Primary: PFS<break/>Secondary: PFS,<break/>BORR, OS</td><td align="left">May 2013/Jun 2014</td><td align="left">NCT01354431</td></tr><tr><td align="left">&#x000a0;Nivolumab vs. everolimus</td><td align="left">III</td><td align="left">Pre-treated advanced or metastatic clear-cell RCC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;822)</td><td align="left">Primary: OS<break/>Secondary: PFS, ORR, DOR, PD-L1 biomarker, safety, DRSPR</td><td align="left">Feb 2016</td><td align="left">NCT01668784</td></tr><tr><td align="left">Other</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Nivolumab or nivolumab&#x000a0;+&#x000a0;ipilimumab vs. bevacizumab</td><td align="left">II</td><td align="left">Recurrent glioblastoma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;260)</td><td align="left">Primary: Safety, OS<break/>Secondary: PFS, ORR, OS</td><td align="left">Jan 2018</td><td align="left">NCT02017717</td></tr><tr><td align="left">&#x000a0;Nivolumab</td><td align="left">II</td><td align="left">Relapsed or refractory diffuse large B-cell lymphoma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;120)</td><td align="left">Primary: ORR<break/>Secondary: DOR, CRR, PFS, ORR</td><td align="left">Feb 2016</td><td align="left">NCT02038933</td></tr><tr><td align="left">&#x000a0;Nivolumab</td><td align="left">III</td><td align="left">Recurrent or metastatic head and neck carcinoma</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;180)</td><td align="left">Primary: PFS, OS<break/>Secondary: ORR</td><td align="left">Jun 2016/Jun 2017</td><td align="left">NCT02105636</td></tr><tr><td align="left">
<italic>Pidilizumab</italic> (<italic>CT-011</italic>)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Prostate cancer</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Pidilizumab&#x000a0;+&#x000a0;sipuleucel-T&#x000a0;+&#x000a0;cyclophosphamide</td><td align="left">II</td><td align="left">Advanced prostate cancer</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;57)</td><td align="left">Primary: Feasibility, immune efficacy<break/>Secondary: PFS, OS</td><td align="left">Dec 2014/Dec 2017</td><td align="left">NCT01420965</td></tr><tr><td align="left">Hematologic malignancies</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Pidilizumab&#x000a0;+&#x000a0;vaccine</td><td align="left">II</td><td align="left">AML</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;75)</td><td align="left">Primary: Toxicity<break/>Secondary: Immune response, tumor regression, TTP</td><td align="left">Sep 2014</td><td align="left">NCT01096602</td></tr><tr><td align="left">&#x000a0;Pidilizumab&#x000a0;+&#x000a0;lenalidomide</td><td align="left">II</td><td align="left">Relapsed or refractory MM</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;53)</td><td align="left">Primary: MTD, OR,<break/>Secondary: TTP, OS, PK</td><td align="left">Jun 2017</td><td align="left">NCT02077959</td></tr><tr><td align="left">
<bold>PD-L1</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">
<italic>MPDL3280A</italic>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Lung cancer</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;MPDL3280A</td><td align="left">II</td><td align="left">PD-L1-positive locally advanced or metastatic NSCLC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;130)</td><td align="left">Primary: ORR<break/>Secondary: ORR, DOR, PFS, safety, PK</td><td align="left">May 2015</td><td align="left">NCT01846416</td></tr><tr><td align="left">&#x000a0;MPDL3280A vs. docetaxel</td><td align="left">II</td><td align="left">Advanced or metastatic NSCLC after platinum failure</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;300)</td><td align="left">Primary: OS<break/>Secondary: OR, PFS, safety, QOL</td><td align="left">Mar 2016/Mar 2017</td><td align="left">NCT01903993</td></tr><tr><td align="left">&#x000a0;MPDL3280A</td><td align="left">II</td><td align="left">PD-L1-positive advanced or metastatic NSCLC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;300)</td><td align="left">Primary: ORR<break/>Secondary: DOR, PFS, OS, safety, PK</td><td align="left">Mar 2018</td><td align="left">NCT02031458</td></tr><tr><td align="left">&#x000a0;MPDL3280A vs. docetaxel</td><td align="left">III</td><td align="left">Advanced or metastatic NSCLC after platinum failure</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;850)</td><td align="left">Primary: OS<break/>Secondary: Safety, OR, PFS, DOR</td><td align="left">Jun 2018</td><td align="left">NCT02008227</td></tr><tr><td align="left">Other</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;MPDL3280A or MPDL3280A&#x000a0;+&#x000a0;bevacizumab vs. sunitinib</td><td align="left">II</td><td align="left">Previously untreated locally advanced or metastatic RCC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;150)</td><td align="left">Primary: PFS<break/>Secondary: irPFS, OR, DOR, OS, PK</td><td align="left">Mar 2016</td><td align="left">NCT01984242</td></tr><tr><td align="left">&#x000a0;MPDL3280A</td><td align="left">II</td><td align="left">Locally advanced or metastatic urothelial bladder cancer</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;330)</td><td align="left">Primary: ORR<break/>Secondary: DOR, PFS, OS, safety, PK</td><td align="left">Nov 2015/Jul 2016</td><td align="left">NCT02108652</td></tr><tr><td align="left">
<italic>MEDI4736</italic>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Lung cancer</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;MEDI4736</td><td align="left">II</td><td align="left">Locally advanced or metastatic NSCLC with &#x02265;2 prior systemic regimens</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;210)</td><td align="left">Primary: ORR<break/>Secondary: DOR, PFS, DCR, OS, DSR, safety, PK</td><td align="left">Apr 2015/Jan 2016</td><td align="left">NCT02087423</td></tr><tr><td align="left">&#x000a0;MEDI4736 vs. docetaxel (sub-study)</td><td align="left">II</td><td align="left">Advanced squamous NSCLC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;undefined for substudy)</td><td align="left">Primary: PFS, OS<break/>Secondary: ORR, safety, irPFS, irOR</td><td align="left">Jun 2022</td><td align="left">NCT02154490</td></tr><tr><td align="left">&#x000a0;MEDI4736 vs. placebo following concurrent chemoradiation</td><td align="left">III</td><td align="left">Stage III unresectable NSCLC</td><td align="left">Recruiting (<italic>n</italic>&#x000a0;=&#x000a0;880)</td><td align="left">Primary: OS, PFS<break/>Secondary: OS, DOR, ORR, PFS</td><td align="left">May 2017/Nov 2020</td><td align="left">NCT02125461</td></tr></tbody></table><table-wrap-foot><p>
<italic>AML</italic> acute myelogenous leukemia, <italic>BORR</italic> best overall response rate, <italic>CRR</italic> complete remission rate, <italic>CTLA-4</italic> cytotoxic T-lymphocyte-associated antigen 4, <italic>DCR</italic> disease control rate, <italic>DMFS</italic> distant metastases-free survival, <italic>DOR</italic> duration of response, <italic>DRSPR</italic> disease-related symptom progression rate, <italic>DSD</italic> duration of stable disease, <italic>DSR</italic> deep sustained response, <italic>IFN</italic> interferon, <italic>irBORR</italic> immune-related best overall response rate, <italic>IRC</italic> independent review committee, <italic>irOR</italic> objective response using immune-related response criteria, <italic>irPFS</italic> immune-related progression free survival, <italic>MM</italic> multiple myeloma, <italic>MTD</italic> maximum tolerated dose, <italic>NSCLC</italic> non-small-cell lung cancer, <italic>OR</italic> overall response, <italic>ORR</italic> objective response rate, <italic>OS</italic> overall survival, <italic>PD-1</italic> programmed death-1, <italic>PD-L1</italic> programmed death ligand 1, <italic>PFS</italic> progression-free survival, <italic>PK</italic> pharmacokinetics, <italic>PR</italic> progression rate, <italic>PSA</italic> prostate specific antigen, <italic>QOL</italic> quality of life, <italic>RCC</italic> renal cell carcinoma, RFS recurrence-free survival, <italic>SCLC</italic> small cell lung cancer, <italic>TTP</italic> time to progression, <italic>TTR</italic> time to response</p><p>
<sup>a</sup>Active (as of July 2014) phase II and III trials with planned enrolment of &#x02265;50 patients are listed</p><p>
<sup>b</sup>Due to the high volume of ipilimumab trials, only those with Bristol-Myers Squibb listed as the sponsor or collaborator are included</p><p>
<sup>c</sup>Investigator-choice chemotherapy (carboplatin&#x000a0;+&#x000a0;paclitaxel, paclitaxel alone, dacarbazine, or temozolomide)</p></table-wrap-foot></table-wrap></p><p>Ipilimumab is also being investigated in the setting of metastatic castration-resistant prostate cancer (mCRPC). In a phase III trial of ipilimumab versus placebo in post-docetaxel patients with mCRPC receiving a single dose of radiotherapy, the primary endpoint of OS was not reached; however, pre-specified subset analyses suggested that ipilimumab may be more active in patients with favorable prognostic factors, including no visceral disease, alkaline phosphatase &#x0003c;1.5 upper limit of normal, and hemoglobin &#x02265;11&#x000a0;g/dL [<xref ref-type="bibr" rid="CR17">17</xref>]. Results from this study support the investigation of ipilimumab in the ongoing phase III, CA184-095 study among chemotherapy-na&#x000ef;ve patients with mCRPC (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR16">16</xref>]).</p></sec><sec id="Sec6"><title>Tremelimumab</title><p>Tremelimumab is a fully human immunoglobulin G (IgG)-2 monoclonal antibody targeting CTLA-4 [<xref ref-type="bibr" rid="CR6">6</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]). Tremelimumab provided durable responses in 6.6&#x000a0;% of patients in a phase II trial of patients with advanced melanoma, as compared with the objective response rates (ORRs) of 5.7 and 10.9&#x000a0;% seen in the phase III trial of ipilimumab with or without vaccine [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. However, the phase III trial of tremelimumab monotherapy failed to demonstrate a statistically significant survival advantage over chemotherapy in first-line treatment of patients with metastatic melanoma [<xref ref-type="bibr" rid="CR21">21</xref>]. Patient selection criteria, dosing regimen, and use of ipilimumab as salvage therapy for patients in the control arm were potential reasons for the lack of survival benefit.</p><p>Tremelimumab showed evidence of activity against previously treated malignant mesothelioma in a small (<italic>N</italic>&#x000a0;=&#x000a0;29) phase II single-arm trial [<xref ref-type="bibr" rid="CR36">36</xref>]. Four patients had partial responses, and 11 patients had stable disease of median duration 7.7&#x000a0;months (range 2.6&#x02013;16.6+), with a median OS of 11.3&#x000a0;months. Based on these results, a phase II trial of tremelimumab in malignant mesothelioma has been initiated (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR16">16</xref>]).</p></sec></sec><sec id="Sec7"><title>Safety of CTLA-4 Inhibitors</title><p>The cumulative safety data across many trials show that agents that inhibit CTLA-4 are generally safe, with unique, but usually manageable, side effects that are linked to their mechanism of stimulating immune responses. Multiple phase II and III trials have characterized these immune-related adverse events (irAEs) of CTLA-4 inhibition. Overall, irAEs were observed in 58&#x02013;63&#x000a0;% of patients treated with ipilimumab, with 5&#x02013;26&#x000a0;% of patients experiencing grade 3/4 irAEs [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]). In the phase III trial investigating ipilimumab treatment with or without vaccine, skin-related irAEs (including pruritus, rash, and erythema) and gastrointestinal irAEs (including diarrhea and colitis) were the most common, occurring in 29&#x02013;44&#x000a0;% of patients; endocrine disorders were reported in 4&#x02013;8&#x000a0;% of patients [<xref ref-type="bibr" rid="CR4">4</xref>]. Some of the more rare adverse events (AEs) (&#x02264;1&#x000a0;% for each) reported during treatment with ipilimumab include uveitis, conjunctivitis, and neuropathy [<xref ref-type="bibr" rid="CR37">37</xref>]. Interestingly, when ipilimumab was given with dacarbazine, immune-mediated grade 3/4 hepatitis occurred in 32&#x000a0;% of patients, while the rates of gastrointestinal events, such as colitis, were lower than expected based on previous trials [<xref ref-type="bibr" rid="CR5">5</xref>]. As adjuvant therapy, ipilimumab had a safety profile generally consistent with that seen in patients with advanced melanoma, although the incidence of some irAEs (e.g. endocrinopathies) was higher. Also, five patients (1&#x000a0;%) in the ipilimumab arm died due to treatment-related AEs versus 0 patients in the placebo group [<xref ref-type="bibr" rid="CR34">34</xref>]. Tremelimumab has a similar irAE profile to ipilimumab. The most common irAEs with tremelimumab were gastrointestinal (18&#x000a0;% grade 3&#x02013;5), dermatologic (rash 33&#x000a0;% all grades, 2&#x000a0;% grade 3&#x02013;5), and endocrine (thyroid/panhypopituitarism/adrenal insufficiency 7&#x000a0;%) in nature [<xref ref-type="bibr" rid="CR21">21</xref>] (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]).<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Preliminary safety data of CTLA-4, PD-1, and PD-L1 targeting agents<sup>a</sup> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Agent name</th><th align="left" colspan="2">Setting</th><th align="left">Phase</th><th align="left">Dosing/description</th><th align="left">Patients (<italic>N</italic>)</th><th align="left">Treatment-related AEs</th><th align="left">Grade 3/4 treatment-related AEs</th><th align="left">Potential immune-related AEs<sup>b</sup>
</th></tr></thead><tbody><tr><td align="left" colspan="9">
<bold>Anti-CTLA-4 agents</bold>
</td></tr><tr><td align="left">&#x000a0;Ipilimumab [<xref ref-type="bibr" rid="CR4">4</xref>]</td><td align="left" colspan="2">Unresectable stage III or IV melanoma</td><td align="left">III</td><td align="left">3&#x000a0;mg/kg q3w, for up to 4 doses</td><td align="left">131</td><td align="left">80 % (<italic>n</italic>&#x000a0;=&#x000a0;105), including fatigue 42&#x000a0;%, nausea 35&#x000a0;%, diarrhea 33&#x000a0;%, decreased appetite 27&#x000a0;%, vomiting 24&#x000a0;%, constipation 21&#x000a0;%; 4 TRD</td><td align="left">Grade 3: 19&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;25), including fatigue 7&#x000a0;%, diarrhea 5&#x000a0;%, dyspnea 3&#x000a0;%, anemia 3&#x000a0;%<break/>Grade 4: 4&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;5), including dyspnea 1 %</td><td align="left">Any grade: 61 % (<italic>n</italic>&#x000a0;=&#x000a0;80), including diarrhea 28 %, pruritus 24 %, rash 19 %, colitis 8 %, endocrine disorders 8 %<break/>Grade 3: 12 % (<italic>n</italic>&#x000a0;=&#x000a0;16), including diarrhea 5 %, colitis 5 %, endocrine disorders 2 %<break/>Grade 4: 2 % (<italic>n</italic>&#x000a0;=&#x000a0;3)</td></tr><tr><td align="left">&#x000a0;Ipilimumab [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="left" colspan="2">mCRPC with bone metastasis</td><td align="left">III</td><td align="left">10&#x000a0;mg/kg q3w, for up to 4 doses, after radiotherapy</td><td align="left">393</td><td align="left">75 % (<italic>n</italic>&#x000a0;=&#x000a0;295); 4 TRD</td><td align="left">ND</td><td align="left">Any grade: 63 % (<italic>n</italic>&#x000a0;=&#x000a0;249)<break/>Grade 3/4: 26 % (<italic>n</italic>&#x000a0;=&#x000a0;101)</td></tr><tr><td align="left">&#x000a0;Tremelimumab [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left" colspan="2">Treatment-na&#x000ef;ve, unresectable stage IIIc or IV melanoma</td><td align="left">III</td><td align="left">15&#x000a0;mg/kg once q90d</td><td align="left">325</td><td align="left">All cause<sup>c</sup>: 96 % (<italic>n</italic>&#x000a0;=&#x000a0;312), including diarrhea 51 %, nausea 34 %, fatigue 33 %, rash 33 %, pruritus 31 %, vomiting 23 %, decreased appetite 21 %; 7 TRD</td><td align="left">All cause<sup>b</sup>:<break/>52 % (<italic>n</italic>&#x000a0;=&#x000a0;170), including diarrhea 18 %, fatigue 6 %, nausea 4 %, vomiting 4 %, decreased appetite 4 %, abdominal pain 4 %</td><td align="left">Any grade AEs included thyroid disorders 5 %, ocular disorders 4 %, hypothalamus and pituitary disorders 2 %<break/>Grade 3/4:<break/>1 % each for thyroid disorders, hypothalamus and pituitary disorders, adrenal insufficiency, hepatitis, pancreatitis</td></tr><tr><td align="left">&#x000a0;Tremelimumab [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left" colspan="2">CTX-resistant advanced malignant mesothelioma</td><td align="left">II</td><td align="left">10&#x000a0;mg/kg once q90d</td><td align="left">29</td><td align="left">Grade 1/2: 90 % (<italic>n</italic>&#x000a0;=&#x000a0;26), including GI AEs 66 %, dermatologic AEs 48 %, fever 34 %</td><td align="left">3 % (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td align="left">None reported<sup>d</sup>
</td></tr><tr><td align="left" colspan="9">
<bold>Anti-PD-1 agents</bold>
</td></tr><tr><td align="left">&#x000a0;Pembrolizumab [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td align="left">Advanced melanoma</td><td align="left" colspan="2">I</td><td align="left">10&#x000a0;mg/kg q2/3w, or 2&#x000a0;mg/kg q3w</td><td align="left">411</td><td align="left">83 % (<italic>n</italic>&#x000a0;=&#x000a0;341), including fatigue 36 %, pruritus 24 %, rash 20 %, diarrhea 16 %, arthralgia 16 %, nausea 12 %, vitiligo 11 %</td><td align="left">12 % (<italic>n</italic>&#x000a0;=&#x000a0;51), including fatigue 2 %; all others &#x0003c;1 %</td><td align="left">Any grade hypothyroidism 8 %, pneumonitis 3 %, hyperthyroidism 1%, colitis &#x0003c;1 %, hepatitis &#x0003c;1 %<break/>Individual grade 3&#x02013;4 events each occurred in &#x0003c;1 %</td></tr><tr><td align="left">&#x000a0;Pembrolizumab [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">NSCLC previously treated with &#x02265;1 systemic regimens</td><td align="left" colspan="2">I</td><td align="left">10&#x000a0;mg/kg q2/3w</td><td align="left">217</td><td align="left">64 %, including fatigue 20 %, arthralgia 9 %, decreased appetite 9 %, pruritus 8 %, diarrhea 7 %</td><td align="left">10 %, including fatigue, arthralgia, nausea, each &#x0003c;1 %</td><td align="left">Any grade rash 6 % and hypothyroidism 5 %<break/>Grade 3&#x02013;4 pneumonitis: 2 % (<italic>n</italic>&#x000a0;=&#x000a0;4)<break/>Grade 3&#x02013;4 arthralgia, neck pain, pneumonitis 2 % (<italic>n</italic>&#x000a0;=&#x000a0;4)</td></tr><tr><td align="left">&#x000a0;Nivolumab [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td align="left">Advanced or recurrent malignancies</td><td align="left" colspan="2">I</td><td align="left">0.1&#x02013;10&#x000a0;mg/kg every 2&#x000a0;weeks, maximum of 12 cycles (4 doses per 8-week cycle)</td><td align="left">296</td><td align="left">70 % (<italic>n</italic>&#x000a0;=&#x000a0;207), including fatigue 24 %, nausea 8 %, decreased appetite 8 %</td><td align="left">14 % (<italic>n</italic>&#x000a0;=&#x000a0;41), including fatigue 2 %, abdominal pain 1 %, hypophosphatemia 1 %, lymphopenia 1 %</td><td align="left">All grades: 41 % (<italic>n</italic>&#x000a0;=&#x000a0;122), including rash 12 %, diarrhea 11 %, pruritus 9 %, pneumonitis 3 %, vitiligo 3 %, infusion-related AEs 3 %, increased TSH 3 %<break/>Grade 3/4: 6 % (<italic>n</italic>&#x000a0;=&#x000a0;18), including pneumonitis 1 %, diarrhea 1 %, increased AST 1 %, increased ALT 1 %, 3 deaths from pneumonitis 1 %</td></tr><tr><td align="left">&#x000a0;Nivolumab [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left">Advanced NSCLC (subset analysis)</td><td align="left" colspan="2">I</td><td align="left">1&#x02013;10&#x000a0;mg/kg q2w maximum of 12 cycles (4 doses per 8-week cycle)</td><td align="left">129</td><td align="left">ND, including fatigue 24 %, decreased appetite 12 %, diarrhea 10 %</td><td align="left">14 %</td><td align="left">All grades: 41 % (<italic>n</italic>&#x000a0;=&#x000a0;53) including skin 16 %, GI 12 %, pulmonary 7 %, endocrinopathies 6 %<break/>Grade 3/4: 5 % (<italic>n</italic>&#x000a0;=&#x000a0;6), including pneumonitis, 3 % (<italic>n</italic>&#x000a0;=&#x000a0;4), GI, hepatic, and infusion reaction&#x000a0;1 %, (<italic>n</italic>&#x000a0;=&#x000a0;1, each); 3 deaths from pneumonitis</td></tr><tr><td align="left">&#x000a0;Nivolumab [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left">Advanced melanoma (subset analysis)</td><td align="left" colspan="2">I</td><td align="left">1&#x02013;10&#x000a0;mg/kg q2w for a maximum of 12 cycles (4 doses per 8-week cycle)</td><td align="left">107</td><td align="left">84 % (<italic>n</italic>&#x000a0;=&#x000a0;90), including fatigue 32 %, rash 23 %, diarrhea 18 %</td><td align="left">22 %, including lymphopenia 3 %, fatigue 2 %, diarrhea 2 %, abdominal pain 2 %</td><td align="left">Any grade: 54 % (<italic>n</italic>&#x000a0;=&#x000a0;58), including skin 36 %, GI 18 %, endocrinopathies 13 %, hepatic 7 %, infusion reaction&#x000a0;6 %, pulmonary 4 %, and renal 2 %<break/>Grade 3/4: 5 % (<italic>n</italic>&#x000a0;=&#x000a0;5), including GI and endocrinopathies 2 % each, and hepatic and renal 1 % each</td></tr><tr><td align="left">&#x000a0;Nivolumab [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">mRCC</td><td align="left" colspan="2">II</td><td align="left">0.3, 2.0, or 10&#x000a0;mg/kg q3w</td><td align="left">168</td><td align="left">67&#x02013;78 %<sup>e</sup>, including fatigue 22&#x02013;35 %, hypersensitivity 0&#x02013;17 %, diarrhea 3&#x02013;15 %, arthralgia 2&#x02013;15 %, nausea 10&#x02013;13%, rash 7&#x02013;13%, pruritus 9&#x02013;11%</td><td align="left">5&#x02013;17 %<sup>e</sup>, including nausea, pruritus, arthralgia 0&#x02013;2 % each</td><td align="left">Any grade<sup>e</sup>: skin 22&#x02013;28 %, hypersensitivity/infusion reaction&#x000a0;4&#x02013;19 %, GI 5&#x02013;15 %, endocrine 5&#x02013;11 %, hepatic 3&#x02013;7 %, pulmonary 4&#x02013;7 %, renal 0&#x02013;2 %<break/>Grade 3/4<sup>e</sup>: skin 0&#x02013;4 %, endocrine 0&#x02013;4 %, hepatic 0&#x02013;4 %, GI 0&#x02013;2 %</td></tr><tr><td align="left">&#x000a0;Pidilizumab [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left">Stage IV progressing melanoma</td><td align="left" colspan="2">II</td><td align="left">1.5 or 6.0&#x000a0;mg/kg q2w up to 54&#x000a0;weeks</td><td align="left">107</td><td align="left">68 %, including fatigue 31 %, diarrhea 16 %, arthralgia 13 %, anemia 11 %, nausea 10 %, hyperglycemia 2 %</td><td align="left">4 %, including arthralgia 1 %, anemia 2 %</td><td align="left">Grade 3 appendicitis, grade 3 arthritis, grade 4 hepatitis and grade 3 pneumonitis 1 % each</td></tr><tr><td align="left" colspan="9">
<bold>Anti-PD-L1 agents</bold>
</td></tr><tr><td align="left">&#x000a0;MPDL3280A [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">Locally advanced or metastatic NSCLC (subset analysis)</td><td align="left" colspan="2">I</td><td align="left">Dose escalation, 1&#x02013;20&#x000a0;mg/kg q3w up to 1&#x000a0;year</td><td align="left">85</td><td align="left">66 % (<italic>n</italic>&#x000a0;=&#x000a0;56), including fatigue 20 %, nausea 14 %, decreased appetite 12 %, dyspnea 9 %, diarrhea 8 %</td><td align="left">11 % (<italic>n</italic>&#x000a0;=&#x000a0;9), including fatigue 2 %, nausea 1 %, dyspnea 1 %, vomiting 1 %</td><td align="left">1 case of grade 3/4 diabetes mellitus 1 %</td></tr><tr><td align="left">&#x000a0;MPDL3280A [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">Metastatic urothelial bladder cancer</td><td align="left" colspan="2">I</td><td align="left">15&#x000a0;mg/kg q3w up to 1&#x000a0;year</td><td align="left">68</td><td align="left">57 % (<italic>n</italic>&#x000a0;=&#x000a0;39), including decreased appetite 12 %, fatigue 12 %, nausea 12 %, pyrexia 9 %, asthenia 7 %</td><td align="left">4 % (<italic>n</italic>&#x000a0;=&#x000a0;3), including asthenia 2 %</td><td align="left">No cases were reported</td></tr><tr><td align="left">&#x000a0;BMS-936559 [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">Advanced or recurrent solid tumors</td><td align="left" colspan="2">I</td><td align="left">Dose escalation, 0.3&#x02013;10&#x000a0;mg/kg q2w in 6-week cycles up to 16 cycles</td><td align="left">207</td><td align="left">61 % (<italic>n</italic>&#x000a0;=&#x000a0;126), including fatigue 16 %, infusion reactions&#x000a0;10 %, rash 9 %, diarrhea 9 %, arthralgia 7 %</td><td align="left">9 % (<italic>n</italic>&#x000a0;=&#x000a0;19), including fatigue 1 %, infusion-related AEs 1 %, lymphopenia 1 %</td><td align="left">39 % (<italic>n</italic>&#x000a0;=&#x000a0;81), including rash 7 %, hypothyroidism 3 %, hepatitis 1 %, one case each of sarcoidosis, endophthalmitis, diabetes mellitus, myasthenia gravis<break/>Grade 3/4: 5 % (<italic>n</italic>&#x000a0;=&#x000a0;10), including infusion reaction &#x0003c;1 %, adrenal insufficiency &#x0003c;1 %</td></tr><tr><td align="left">&#x000a0;MEDI4736 [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">Advanced solid tumors</td><td align="left" colspan="2">I</td><td align="left">10&#x000a0;mg/kg q2w up to 1&#x000a0;year</td><td align="left">346</td><td align="left">39 % (<italic>n</italic>&#x000a0;=&#x000a0;135), including fatigue 13 %, rash/pruritus 9 %, vomiting 5 %, diarrhea 5 %</td><td align="left">6 % (<italic>n</italic>&#x000a0;=&#x000a0;20), including fatigue 1 %, elevated AST/ALT 1 %, vomiting, hypothyroidism, hyperglycemia, rash/pruritus, all &#x0003c;1 %</td><td align="left">All grades: elevated AST/ALT 4 %, hypothyroidism 2 %, hyperthyroidism 1 %, pneumonitis 1 %, peripheral neuropathy 1 %</td></tr></tbody></table><table-wrap-foot><p>
<italic>AE</italic> adverse event, <italic>ALT</italic> alanine aminotransferase, <italic>AST</italic> aspartate aminotransferase, <italic>CTLA-4</italic> cytotoxic T-lymphocyte-associated antigen 4, <italic>CTX</italic> chemotherapy, <italic>GI</italic> gastrointestinal, <italic>mCRPC</italic> metastatic castration-resistant prostate cancer, <italic>mRCC</italic> metastatic renal cell carcinoma, <italic>ND</italic> no data, <italic>NSCLC</italic> non-small cell lung cancer, <italic>PD-1</italic> programmed death-1, <italic>PD-L1</italic> programmed death ligand 1, <italic>qxd</italic> every x days, <italic>qxw</italic> every x weeks, <italic>TRD</italic> treatment-related deaths, <italic>TSH</italic> thyroid stimulating hormone</p><p>
<sup>a</sup>Monotherapy trials in solid tumors were included</p><p>
<sup>b</sup>As determined by the investigator</p><p>
<sup>c</sup>Treatment-related AEs not available</p><p>
<sup>d</sup>At 15&#x000a0;mg/kg the following immune-related AEs were reported: Grade 3 colitis or diarrhea: 7&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;2); Grade 3 Guillain-Barr&#x000e9;-like peripheral neuropathy: 3&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;1); Grade 4 increases in transaminases and pancreatic enzymes: 3&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;1) [<xref ref-type="bibr" rid="CR40">40</xref>]</p><p>
<sup>e</sup>Depending on dose</p></table-wrap-foot></table-wrap></p><p>irAEs for CTLA-4 inhibitors tend to occur during the induction period or first 12&#x000a0;weeks of therapy, but, in rare cases, can occur in the weeks and even months following discontinuation of therapy [<xref ref-type="bibr" rid="CR37">37</xref>]. Grade 2 irAEs are usually responsive to interruption of therapy and institution of low-dose steroids (0.5&#x000a0;mg/kg/day of prednisone), and grade 3 and higher irAEs are generally responsive to high-dose steroids (1&#x02013;2&#x000a0;mg/kg/day of prednisone or equivalent), although the steroid-refractory patients (reported as 2&#x02013;8&#x000a0;% of patients) [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR41">41</xref>] may require the use of alternate immunosuppressive agents, such as infliximab (5&#x000a0;mg/kg) once every 2&#x000a0;weeks until symptom resolution, followed by a prolonged steroid taper [<xref ref-type="bibr" rid="CR42">42</xref>]. Prompt recognition, management, and monitoring of grade 2 and higher irAEs are critical for the successful resolution of these toxicities, although such events can often take weeks to months to return to baseline. Algorithms for the management of irAEs with ipilimumab have been published by Fecher et al. [<xref ref-type="bibr" rid="CR37">37</xref>]. Unfortunately, prophylactic steroids and other preventive strategies to avoid irAEs have not shown clinical benefit to date [<xref ref-type="bibr" rid="CR37">37</xref>]. An interesting and consistent observation is that a higher incidence of irAEs, particularly grade 3/4 irAEs, has been associated with a higher proportion of patients eventually achieving an objective response [<xref ref-type="bibr" rid="CR43">43</xref>]. However, as grade 3/4 irAEs can be life threatening, it is recommended that patients experiencing severe irAEs discontinue ipilimumab [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p></sec></sec><sec id="Sec8"><title>Programmed Death-1 (PD-1) and Programmed Death Ligand 1 (PD-L1)</title><sec id="Sec9"><title>Background</title><p>PD-1 (CD279) is also a co-inhibitory molecule that plays an important role in the balance of tumor immunity and inflammatory reactions [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. However, in contrast to CTLA-4, PD-1 appears to play a greater role in limiting and modulating the activity of T cells in peripheral tissues and organs during inflammatory responses in an effort to prevent host tissue damage. PD-1 expression is induced on activated T cells, and the interaction between PD-1 and one of its ligands&#x02014;typically PD-L1 (B7-H1, CD274) or PD-L2 (B7-DC, CD273)&#x02014;on the surface of tumors leads to a diminished antitumor response and has been associated with a poorer patient outcome [<xref ref-type="bibr" rid="CR44">44</xref>]. High levels of PD-1 expression on antigen-experienced CD8<sup>+</sup> T cells are associated with the loss of effector functions, including the ability of T cells to proliferate and express interleukin (IL)-2, tumor necrosis factor (TNF)-&#x003b1;, and interferon (IFN)-&#x003b3;&#x02014;a process termed T-cell &#x02018;exhaustion&#x02019; or &#x02018;tolerance&#x02019;. In this state, tumor-infiltrating lymphocytes become tolerant and are less capable of carrying out antitumor immune responses as a result of chronic antigen exposure and prolonged negative immune regulation. While both CTLA-4 and PD-1 are immune checkpoint inhibitors, CTLA-4 is thought to act earlier in the process of T-cell activation, whereas PD-1 plays a role in attenuating T-cell responses later in the process, after T cells have migrated to the tumor microenvironment [<xref ref-type="bibr" rid="CR44">44</xref>] (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Inhibiting the CTLA-4 and PD-1 immune checkpoint pathways to restore antitumor immune responses. In peripheral lymphoid organs and tissues, anti-CTLA-4 antibodies block CTLA-4 from binding CD80/86 on APCs and prevent T-cell inhibition. In the tumor microenvironment, PD-L1 and/or PD-L2 expression inhibits PD-1-expressing T cells. Interruption of PD-1:PD-L1 and PD-1:PD-L2 binding by anti-PD-1 antibodies or interruption of PD-1:PD-L1 binding by anti-PD-L1 antibodies restores T-cell immune responses. <italic>APC</italic> antigen-presenting cell, <italic>CTLA-4</italic> cytotoxic T-lymphocyte-associated antigen 4, <italic>MHC</italic> major histocompatibility complex, <italic>PD-1</italic> programmed death-1, <italic>PD-L1</italic> programmed death ligand 1, <italic>PD-L2</italic> programmed death ligand 2, <italic>TCR</italic> T-cell receptor</p></caption><graphic xlink:href="40265_2014_305_Fig2_HTML" id="MO2"/></fig></p><p>Given these observations, both PD-1 and PD-L1 antibody blockade may be a promising target for cancer immunotherapy (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Anti-PD-1 antibodies are designed to inhibit PD-1 from engaging with any of its ligands, thereby preventing both PD-1:PD-L1 and PD-1:PD-L2 binding. In contrast, anti-PD-L1 agents prevent PD-1:PD-L1 binding, but not necessarily PD-1:PD-L2 binding. There is evidence that PD-L1 may bind CD80 (B7-1) on T cells, leading to a down-regulatory signal; hence, anti-PD-L1 could inhibit this interaction as well [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Given the current understanding that PD-1:PD-L1 interactions are a predominant mechanism of tumor immune evasion, whether agents targeting PD-1 versus PD-L1 will have different clinical profiles is unknown.</p><p>To date, all data reported for PD-1 pathway inhibitors have been in phase I or II studies without control arms. The ongoing phase II and III trials that include control arms should provide data with greater context. Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> lists PFS and OS data from historical controls and studies where these data were available. However, as the studies differ greatly in terms of patient characteristics, study sizes, and length of follow-up, direct comparisons should be made with great caution.</p></sec><sec id="Sec10"><title>Efficacy with PD-1 Inhibitors</title><sec id="Sec11"><title>Pembrolizumab (MK-3475)</title><p>Pembrolizumab (MK-3475) is a humanized IgG4 monoclonal antibody against PD-1 [<xref ref-type="bibr" rid="CR7">7</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]). A phase I study, including expansion cohorts, evaluated pembrolizumab treatment in patients with advanced melanoma who had previously received or not received ipilimumab [<xref ref-type="bibr" rid="CR7">7</xref>]. The overall response rate across all doses was 34&#x000a0;%; 88&#x000a0;% of responses were ongoing at the time of analysis and the median duration of response had not been reached. Prior treatment with immunotherapy, including ipilimumab and IL-2, did not preclude activity of pembrolizumab, nor were higher rates of AEs observed in patients who had received previous immunotherapy compared with those who had not. Preliminary survival data of pembrolizumab and other PD-1 pathway agents is listed in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>Pembrolizumab was also investigated in a phase I study in patients with previously treated NSCLC [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Interim data analysis revealed that, in a cohort of 217 patients with NSCLC, the ORR was 18&#x000a0;% based on immune-related response criteria (irRC), and the median OS was 51&#x000a0;weeks. irRC have been used primarily to assess responses in patients with melanoma, and have not been validated in other cancers [<xref ref-type="bibr" rid="CR46">46</xref>]. Responses were seen in patients with non-squamous and squamous histology, and in current/former and never smokers. [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. As a first-line therapy for NSCLC, pembrolizumab reported preliminary ORRs of 47&#x000a0;% by irRC. Median PFS was 27&#x000a0;weeks (Response Evaluation Criteria in Solid Tumors [RECIST]) and 37&#x000a0;weeks (irRC) [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>Pembrolizumab also showed antitumor activity in patients with head and neck cancer in a phase I study [<xref ref-type="bibr" rid="CR47">47</xref>]. Responses were seen in 20&#x000a0;% (11/56) of evaluable patients, which included human papillomavirus-positive and -negative tumors (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR16">16</xref>]).</p></sec><sec id="Sec12"><title>Nivolumab</title><p>Nivolumab (BMS-936558) is a fully human IgG4 PD-1 immune checkpoint inhibitor [<xref ref-type="bibr" rid="CR8">8</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]). A phase I, dose-escalating study in multiple tumor types reported objective responses with nivolumab in a substantial portion of patients with melanoma, NSCLC, or renal cell carcinoma (RCC), but no objective responses in patients with colorectal cancer (CRC) or CRPC [<xref ref-type="bibr" rid="CR8">8</xref>]. In patients with melanoma treated with nivolumab across all doses in the phase I trial, the ORR was 32&#x000a0;% and the median duration of response was 99&#x000a0;weeks. The median OS was 17.3&#x000a0;months and 1-, 2-, and 3-year survival rates were 63, 48, and 41&#x000a0;%, respectively [<xref ref-type="bibr" rid="CR22">22</xref>] (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]).</p><p>In the phase I trial among patients with NSCLC and across all doses, the ORR was 17&#x000a0;% (22/129), the estimated median response duration was 74&#x000a0;weeks, and overall 1- and 2-year survival rates were 42 and 24&#x000a0;%, respectively [<xref ref-type="bibr" rid="CR28">28</xref>]. Ongoing trials are evaluating nivolumab alone or in combination with chemotherapy, erlotinib, or ipilimumab in patients with chemotherapy-na&#x000ef;ve NSCLC, and have reported initial evidence of antitumor activity [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. With first-line nivolumab monotherapy in a phase I trial, the initial ORR was 30&#x000a0;%, median PFS was 36.1&#x000a0;weeks, and median OS was not reached (range 13.3&#x02013;89.1+) in 20 evaluable patients. The 1-year OS rate was 75&#x000a0;% [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>In phase II study in patients with previously-treated RCC, the overall response rate was 21&#x000a0;% (35/168), with the majority of responses lasting &#x0003e;1&#x000a0;year [<xref ref-type="bibr" rid="CR33">33</xref>]. Across the evaluated doses, the PFS ranged from 2.7 to 4.2 months, and the median OS ranged from 18.2 to 24.7&#x000a0;months. The survival rate was approximately 35&#x000a0;% at 2.5&#x000a0;years [<xref ref-type="bibr" rid="CR33">33</xref>] (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]). Phase II and III trials of nivolumab are ongoing in melanoma, NSCLC, RCC, and squamous head and neck cancer (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR16">16</xref>]).</p></sec><sec id="Sec13"><title>Pidilizumab (CT-011)</title><p>Pidilizumab (CT-011) is a humanized anti-PD-1 IgG1 monoclonal antibody [<xref ref-type="bibr" rid="CR9">9</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]). Pidilizumab was evaluated in patients with stage IV melanoma in a phase II open-label study. The ORR using irRC was 6&#x000a0;%, the median PFS was 1.9&#x000a0;months, and the 1-year survival rate was 65&#x000a0;% [<xref ref-type="bibr" rid="CR23">23</xref>] (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]).</p><p>Pidilizumab has also shown evidence of efficacy in patients with hematologic malignancies [<xref ref-type="bibr" rid="CR51">51</xref>]. Separately, pidilizumab after autologous hematopoietic stem-cell transplantation (AHSCT) was evaluated in a phase II trial in patients with diffuse large B-cell lymphoma (DLBCL) or primary mediastinal large B-cell lymphoma [<xref ref-type="bibr" rid="CR9">9</xref>]. A total of 66 patients completed all treatment cycles, and PFS at 16&#x000a0;months from the start of treatment was 72&#x000a0;%. This compares favorably with the PFS rate at 18&#x000a0;months of 52&#x000a0;% in a historical group of patients with DLBCL with similar characteristics (i.e., would have met the eligibility criteria for the study, including no progression or relapse within 2&#x000a0;months of AHSCT) who had received high-dose chemotherapy followed by AHSCT [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Among the 35 patients with measurable disease after transplant, the overall response rate with pidilizumab treatment was 51&#x000a0;%, and the complete remission rate was 34&#x000a0;% [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec14"><title>AMP-224</title><p>AMP-224 is a recombinant fusion protein comprising the extracellular domain of PD-L2 and the Fc region of human IgG [<xref ref-type="bibr" rid="CR10">10</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]). This agent is designed to bind PD-1, and preclinical studies suggest its mechanism of action may differ from monoclonal antibody blockade. A phase I trial evaluating the safety of AMP-224 in patients with advanced cancer is ongoing (NCT01352884) [<xref ref-type="bibr" rid="CR53">53</xref>]. Infusion reactions were common, occurring in 69&#x000a0;% of patients across dose cohorts. It is unclear whether this study is moving forward, as a high rate of infusion reactions and lack of efficacy have been observed compared with other PD-1 inhibitors.</p></sec></sec><sec id="Sec15"><title>Safety of PD-1 Inhibitors</title><p>While no head-to-head trials have been conducted, the safety profiles of the anti-PD-1 agents seem to be generally similar. In the largest and most mature studies of pembrolizumab and nivolumab, grade 3/4 treatment-related AEs were reported in 10&#x02013;22&#x000a0;% of patients [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. The most common treatment-related AE was fatigue in all studies (20&#x02013;36&#x000a0;% all grades, 2&#x000a0;% grade 3/4). Potential immune-related select AEs were also commonly reported: dermatologic toxicities (pruritus &#x02264;24&#x000a0;% all grades, &#x0003c;1&#x000a0;% grade 3/4; rash 6&#x02013;20&#x000a0;% all grades, &#x0003c;1&#x000a0;% grade 3/4; vitiligo &#x02264;11&#x000a0;% all grades, 0&#x000a0;% grade 3/4), gastrointestinal toxicities (diarrhea 7&#x02013;16&#x000a0;% all grades, &#x02264;1&#x000a0;% grade 3/4; nausea 6&#x02013;12&#x000a0;% all grades, &#x0003c;1&#x000a0;% grade 3/4), and endocrinopathies (hypothyroidism 2&#x02013;8&#x000a0;% all grades, &#x0003c;1&#x000a0;% grade 3/4; hyperthyroidism 1&#x02013;2&#x000a0;% all grades, &#x0003c;1&#x000a0;% grade 3/4). Arthralgia (all grades) was reported in 4&#x02013;16&#x000a0;% of patients, and grade 3/4 in &#x0003c;1&#x000a0;%. Pneumonitis of all grades was noted in 3&#x000a0;% of pembrolizumab- or nivolumab-treated patients, with &#x02264;1&#x000a0;% of patients developing grade 3/4 pneumonitis. Although rare, three deaths due to pneumonitis in nivolumab-treated patients are concerning. Nivolumab or pembrolizumab in patients who had received prior ipilimumab showed similar safety profiles to those of ipilimumab-na&#x000ef;ve patients, supporting the sequential use of these therapies [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>].</p></sec><sec id="Sec16"><title>Efficacy with PD-L1 Inhibitors</title><sec id="Sec17"><title>MPDL3280A</title><p>MPDL3280A is a human anti-PD-L1 monoclonal antibody [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]). MPDL3280A is being assessed in a dose-ranging phase I study in patients with multiple tumor types. Interim results from 53 evaluable patients with NSCLC revealed an ORR of 23&#x000a0;% in patients across squamous and non-squamous histologies, including several patients with rapid tumor shrinkage [<xref ref-type="bibr" rid="CR39">39</xref>]. Some patients (not included in the ORR) had delayed responses after apparent radiographic progression. Most responses were ongoing at the time of analysis. The ORR in patients with RCC was 13&#x000a0;%; durable responses were seen in patients with clear cell and non-clear cell disease [<xref ref-type="bibr" rid="CR11">11</xref>]. In patients with urothelial bladder cancer, the ORR was 25&#x000a0;% (17/67) [<xref ref-type="bibr" rid="CR12">12</xref>]. Phase II and III trials evaluating MPDL3280A in advanced lung cancer, advanced RCC, and urothelial bladder cancer are ongoing (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR16">16</xref>]).</p></sec><sec id="Sec18"><title>BMS-936559</title><p>BMS-936559 is a fully human IgG4 monoclonal antibody directed against PD-L1 [<xref ref-type="bibr" rid="CR13">13</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]). The safety and activity of BMS-936559 was assessed in a phase I dose-escalating study in patients with advanced solid tumors [<xref ref-type="bibr" rid="CR13">13</xref>]. Clinical activity was observed in patients with melanoma, NSCLC, RCC, CRC, ovarian, or pancreatic cancer, but not for patients with gastric or breast cancer. ORRs for patients with melanoma, NSCLC, RCC, and ovarian cancer were 17, 10, 12, and 6&#x000a0;%, respectively, and responses lasted for &#x02265;1&#x000a0;year in 8 of 16 patients with at least 1&#x000a0;year of follow-up. No additional trials of BMS-936559 are currently listed in ClinicalTrials.gov [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec19"><title>MEDI4736</title><p>MEDI4736 is a human IgG1 monoclonal antibody that binds PD-L1 [<xref ref-type="bibr" rid="CR14">14</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]). MEDI4736 is being investigated in multiple tumor types, including melanoma, NSCLC, squamous head and neck cancer, and pancreatic cancer in a phase I trial. A preliminary analysis reported ORRs of 13&#x000a0;% (6/47) in patients with NSCLC and 14&#x000a0;% (3/22) in patients with squamous head and neck cancer, and evidence of activity against pancreatic and gastroesophageal cancer [<xref ref-type="bibr" rid="CR14">14</xref>]. Numerous studies of MEDI4736 are planned or ongoing in patients with NSCLC or other malignancies (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR16">16</xref>]).</p></sec></sec><sec id="Sec20"><title>Safety of PD-L1 Inhibitors</title><p>The types of AEs reported with PD-L1 agents seem similar to those targeting PD-1, but the incidence of AEs appears to be lower. The reported rate of grade 3/4 treatment-related AEs across studies and tumor types ranged from 4 to 13&#x000a0;% [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Fatigue (12&#x02013;20&#x000a0;% all grades, 0&#x02013;2&#x000a0;% grade 3/4), gastrointestinal AEs (diarrhea 5&#x02013;9&#x000a0;% all grades, 0&#x000a0;% grade 3/4; nausea 6&#x02013;14&#x000a0;% all grades, 0&#x02013;1&#x000a0;% grade 3/4), dermatologic AEs (rash 7&#x02013;9&#x000a0;% all grades, &#x0003c;1&#x000a0;% grade 3/4; pruritus 6&#x000a0;% all grades, &#x0003c;1&#x000a0;% grade 3/4), and endocrinopathies (hypothyroidism 2&#x02013;3&#x000a0;% all grades, &#x0003c;1&#x000a0;% grade 3/4) were the most common.</p><p>BMS-936559 had a higher reported rate of infusion-related reactions (10&#x000a0;% all grades, &#x02264;1&#x000a0;% grade 3/4) and arthralgia (7&#x000a0;% all grades, 0&#x000a0;% grade 3/4) than other PD-L1-targeting agents [<xref ref-type="bibr" rid="CR13">13</xref>] (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]).</p></sec><sec id="Sec21"><title>PD-L1 as a Predictive Biomarker</title><p>Emerging evidence suggests that PD-L1 expression on pre-treatment tumor specimens may be a predictive biomarker of efficacy with PD-1 pathway inhibitors. Across agents, studies, and tumor types, antitumor activity was generally higher against PD-L1-positive tumors versus tumors with low or negative staining for PD-L1 (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR56">56</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref>]). However, the methodology, amount of staining (or &#x02018;cut-off&#x02019;) required to qualify as a PD-L1-positive tumor and timing of sample collection (archival or immediately pre-treatment) varied across studies. Thus, while these preliminary findings are encouraging, data on tumor PD-L1 expression as a potential predictive biomarker are evolving, and prospective validation will be needed.<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>PD-L1 expression and association with clinical activity [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR56">56</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Agent</th><th align="left">Setting</th><th align="left">Cut-off for PD-L1<sup>+a</sup>
</th><th align="left">ORR in pts with PD-L1<sup>+</sup> tumors, % (<italic>n</italic>/<italic>N</italic>)</th><th align="left">ORR in pts with PD-L1<sup>-</sup>low/negative tumors, % (<italic>n/N</italic>)</th><th align="left">Median PFS in pts with PD-L1<sup>+</sup> tumors</th><th align="left">Median PFS in pts with PD-L1<sup>&#x02212;</sup> low/negative tumors</th><th align="left">Reference(s)</th></tr></thead><tbody><tr><td align="left">Pembrolizumab</td><td align="left">Advanced melanoma</td><td align="left">&#x02265;1&#x000a0;%<sup>b</sup>
</td><td char="(" align="char">51 (ND)</td><td char="(" align="char">6 (ND)</td><td align="left">12&#x000a0;months</td><td align="left">3&#x000a0;months</td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left">Pembrolizumab</td><td align="left">Advanced NSCLC</td><td align="left">&#x02265;50&#x000a0;%<sup>b</sup>
</td><td char="(" align="char">37 (15/41)</td><td char="(" align="char">11 (10/88)</td><td align="left">14.0&#x000a0;weeks</td><td align="left">9.3&#x000a0;weeks</td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left">Nivolumab</td><td align="left">Previously-treated melanoma</td><td align="left">&#x02265;5&#x000a0;%<sup>b</sup>
</td><td char="(" align="char">44 (8/18)</td><td char="(" align="char">13 (3/23)</td><td align="left">9&#x000a0;months</td><td align="left">2&#x000a0;months</td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left">Nivolumab</td><td align="left">Previously-treated NSCLC</td><td align="left">&#x02265;5&#x000a0;%<sup>b</sup>
</td><td char="(" align="char">15 (5/33)</td><td char="(" align="char">14 (5/35)</td><td align="left">3.6&#x000a0;months</td><td align="left">1.8&#x000a0;months</td><td align="left">[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left">Nivolumab</td><td align="left">CTX-na&#x000ef;ve NSCLC</td><td align="left">&#x02265;5&#x000a0;%<sup>b</sup>
</td><td char="(" align="char">50 (5/10)</td><td char="(" align="char">0 (0/7)</td><td align="left">45.6&#x000a0;weeks</td><td align="left">36.1&#x000a0;weeks</td><td align="left">[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td align="left">Nivolumab</td><td align="left">RCC</td><td align="left">&#x02265;5&#x000a0;%<sup>b</sup>
</td><td char="(" align="char">22 (4/18)</td><td char="(" align="char">8 (3/38)</td><td align="left">ND</td><td align="left">ND</td><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left">MPDL3280A</td><td align="left">Previously-treated NSCLC</td><td align="left">Score&#x000a0;=&#x000a0;3 (highly positive)<sup>c</sup>
</td><td char="(" align="char">83 (5/6)</td><td char="(" align="char">20 (4/20)</td><td align="left">ND</td><td align="left">ND</td><td align="left">[<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left">MPDL3280A</td><td align="left">RCC</td><td align="left">Positive staining<sup>c</sup>
</td><td char="(" align="char">20 (2/10)</td><td char="(" align="char">10 (2/21)</td><td align="left">ND</td><td align="left">ND</td><td align="left">[<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left">MPDL3280A</td><td align="left">Urothelial bladder cancer</td><td align="left">&#x02265;5 %<sup>d</sup>
</td><td char="(" align="char">43 (ND)</td><td char="(" align="char">11 (ND)</td><td align="left">ND</td><td align="left">ND</td><td align="left">[<xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr><td align="left">MEDI4736</td><td align="left">NSCLC</td><td align="left">Undefined</td><td char="(" align="char">39 (5/13)</td><td char="(" align="char">5 (1/19)</td><td align="left">ND</td><td align="left">ND</td><td align="left">[<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td align="left">MEDI4736</td><td align="left">Head and neck cancer</td><td align="left">Undefined</td><td char="(" align="char">50 (2/4)</td><td char="(" align="char">6 (1/16)</td><td align="left">ND</td><td align="left">ND</td><td align="left">[<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr></tbody></table><table-wrap-foot><p>
<italic>CTX</italic> chemotherapy, <italic>ND</italic> no data, <italic>NSCLC</italic> non-small cell lung cancer, <italic>RCC</italic> renal cell carcinoma, <italic>PD-L1</italic> programmed death ligand 1, <italic>pts</italic> patients</p><p>
<sup>a</sup>Amount of staining required to qualify as a PD-L1<sup>+</sup> tumor</p><p>
<sup>b</sup>Membrane staining of tumor cells</p><p>
<sup>c</sup>Staining of tumor-infiltrating immune cells; amount of staining to qualify as a PD-L1<sup>+</sup> tumor was not defined</p><p>
<sup>d</sup>Staining of tumor-infiltrating immune cells</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec22"><title>Immunotherapy Clinical Response Patterns</title><p>Across the various immunotherapy clinical development programs, investigators have observed response patterns that sometimes differ from the conventional responses observed with cytotoxic agents. Standard response criteria may not capture or adequately describe the responses produced by novel immunotherapy; thus, clinical trials may not always capture the full clinical benefit to patients who receive immunotherapy. To better characterize this pattern of response, new irRC were created that accounted for antitumor response based on total measurable tumor burden as measured by the sum of index lesions and new measurable lesions [<xref ref-type="bibr" rid="CR46">46</xref>]. Time point response assessment was also incorporated into the criteria, as two observations at least 4&#x000a0;weeks apart were necessary to help distinguish progression from &#x02018;pseudoprogression&#x02019;, in which there is an initial increase in tumor size followed by tumor shrinkage. The differences between World Health Organization (WHO) criteria and the new irRC are listed in Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref> [<xref ref-type="bibr" rid="CR46">46</xref>].<table-wrap id="Tab6"><label>Table&#x000a0;6</label><caption><p>Comparison between WHO criteria and the irRC [<xref ref-type="bibr" rid="CR46">46</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">WHO</th><th align="left">irRC</th></tr></thead><tbody><tr><td align="left">New, measurable lesions (i.e., &#x02265;5&#x000a0;&#x000d7;&#x000a0;5&#x000a0;mm)</td><td align="left">Always represent PD</td><td align="left">Incorporated into tumor burden</td></tr><tr><td align="left">New, non-measurable lesions (i.e., &#x0003c;5&#x000a0;&#x000d7;&#x000a0;5&#x000a0;mm)</td><td align="left">Always represent PD</td><td align="left">Do not define progression (but preclude irCR)</td></tr><tr><td align="left">Non-index lesions</td><td align="left">Changes contribute to defining BOR of CR, PR, SD, and PD</td><td align="left">Contribute to defining irCR (complete disappearance required)</td></tr><tr><td align="left">CR</td><td align="left">Disappearance of all lesions in two consecutive observations not less than 4&#x000a0;weeks apart</td><td align="left">Disappearance of all lesions in two consecutive observations not less than 4&#x000a0;weeks apart</td></tr><tr><td align="left">PR</td><td align="left">&#x02265;50&#x000a0;% decrease in SPD of all index lesions vs. baseline in two observations at least 4&#x000a0;weeks apart, in absence of new lesions or unequivocal progression of non-index lesions</td><td align="left">&#x02265;50&#x000a0;% decrease in tumor burden vs. baseline in two observations at least 4&#x000a0;weeks apart</td></tr><tr><td align="left">SD</td><td align="left">50 % decrease in SPD vs. baseline cannot be established nor 25 % increase vs. nadir, in absence of new lesions or unequivocal progression of non-index lesions</td><td align="left">50 % decrease in tumor burden vs. baseline cannot be established nor 25 % increase vs. nadir</td></tr><tr><td align="left">PD</td><td align="left">At least 25 % increase in SPD vs. nadir and/or unequivocal progression of non-index lesions and/or appearance of new lesions (at any single time point)</td><td align="left">At least 25 % increase in tumor burden vs. nadir (at any single time point) in two consecutive observations at least 4&#x000a0;weeks apart</td></tr></tbody></table><table-wrap-foot><p>Reproduced with permission from Wolchok et al. [<xref ref-type="bibr" rid="CR46">46</xref>]</p><p>
<italic>BOR</italic> best overall response, <italic>CR</italic> complete response, <italic>irCR</italic> immune-related complete response, <italic>PD</italic> progressive disease, <italic>PR</italic> partial response, <italic>SD</italic> stable disease, <italic>SPD</italic> sum of the products of the two largest perpendicular diameters, <italic>WHO</italic> World Health Organization</p></table-wrap-foot></table-wrap></p><p>It has also been determined that some of these new response patterns to immune therapies are associated with a favorable survival outcome and may include the following:<list list-type="bullet"><list-item><p>Stable disease, which in some cases may be followed by slow and steady decline of tumor burden. Durable, stable disease lasting months or even years has been observed in some patients.</p></list-item><list-item><p>Reduction after an initial increase in tumor burden; this observation has been associated with T-cell infiltration into the tumor, giving the appearance of progressive disease.</p></list-item><list-item><p>Reduction in total tumor burden during or after the appearance of new lesions, possibly due to the unique mechanism of action of immunotherapy, as the activated immune system may take some time to mount an effective antitumor response.</p></list-item></list></p><p>Time to response appears to be faster for agents that block PD-1 or PD-L1 compared with the many weeks it may take to observe tumor shrinkage in response to anti-CTLA-4 treatment [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Additionally, response rates in patients given anti-PD-1 or anti-PD-L1 treatment may be higher than in those receiving anti-CTLA-4, although head-to-head trial data are not yet available.</p></sec><sec id="Sec23"><title>Other Immune Targets&#x02014;Inhibitory and Stimulatory</title><p>In addition to CTLA-4 and PD-1, other classes of inhibitory and stimulatory molecules have potential to be used as anticancer immunotherapy. One inhibitory molecule that has drawn much attention recently is lymphocyte activation gene-3 (LAG-3), a CD4 homolog that binds to MHC class II molecules (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). LAG-3 is expressed on activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells, as well as B cells, natural killer cells, and tumor-infiltrating lymphocytes, and is thought to negatively regulate T-cell expansion by limiting T-cell activation. However, LAG-3 knockout mice do not develop overt autoimmunity, suggesting that it plays a more subtle role in regulating T-cell function than the checkpoint molecules CTLA-4 and PD-1 [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. While LAG-3 is another immune checkpoint that may be important in the immune response to cancer, blockade of this pathway has not been clinically evaluated to the same extent as the CTLA-4 and PD-1 pathways [<xref ref-type="bibr" rid="CR3">3</xref>]. However, based on the success of other checkpoint molecules as targets for anticancer therapy, research is now ongoing to assess the possible clinical value of LAG-3 blockade. IMP321 is a soluble LAG-3 Ig fusion protein and MHC class II agonist (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]); it has been combined with gemcitabine in a phase I study in patients with advanced pancreatic adenocarcinoma [<xref ref-type="bibr" rid="CR15">15</xref>]. IMP321 plus gemcitabine appears to be a well tolerated regimen that has not resulted in any serious AEs in patients to date; however, limited antitumor responses were attributed to the low doses of IMP321. A small study combining IMP321 and melanoma-associated antigen immunization in patients with melanoma is ongoing (NCT01308294).</p><p>A variety of other molecules that similarly regulate T-cell activation, tolerance/exhaustion, anergy, and even T-cell death are currently being assessed as potential targets for anticancer therapy. One of these inhibitory molecules is T-cell immunoglobulin and mucin domain 3 (TIM3), which is a member of the TIM family (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). TIM3 is expressed by IFN-&#x003b3;-secreting helper T (T<sub>H</sub>1) cells, as well as dendritic cells, monocytes, and T cells [<xref ref-type="bibr" rid="CR61">61</xref>]. When bound to its ligand, galectin-9, TIM3 induces T<sub>H</sub>1 cell death [<xref ref-type="bibr" rid="CR62">62</xref>]. Studies of TIM3-deficient mice suggest that the TIM3 pathway inhibits the expansion and effector functions of T<sub>H</sub>1 cells and may be important for tolerance induction of T<sub>H</sub>1 cells [<xref ref-type="bibr" rid="CR63">63</xref>]. Administration of a TIM3 fusion protein resulted in hyperproliferation of T<sub>H</sub>1 cells and inflammatory cytokine release, suggesting a ligand for TIM3 is also expressed by these cells.</p><p>Glucocorticoid-induced TNF receptor-related gene (GITR) can provide a co-stimulatory signal to both CD4<sup>+</sup>- and CD8<sup>+</sup>-na&#x000ef;ve T-cells, particularly when T-cell receptor stimulation is weak [<xref ref-type="bibr" rid="CR64">64</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). T cells that do not express GITR are more prone to activation-induced cell death, suggesting that GITR-mediated stimulation may enhance the survival of activated T cells. Also, preclinical studies showed that agonist anti-GITR antibodies could reverse regulatory T-cell suppression of effector T cells. Data from murine models suggest that GITR blockade may be most effective when combined with melanoma vaccination strategies and not as monotherapy [<xref ref-type="bibr" rid="CR65">65</xref>]. Currently, a phase I dose-escalation trial of an anti-GITR monoclonal antibody (TRX518) is recruiting patients with unresectable stage III or IV melanoma or other solid tumor malignancies (NCT01239134).</p></sec><sec id="Sec24"><title>Combination Strategies</title><p>Despite promising results as monotherapies, there remains a clear need to increase the number of patients with malignancies that can benefit from immune checkpoint inhibitors. The increasing arsenal of targeted and immune-based therapies affords opportunities for sequencing and combination strategies to improve outcomes. Indeed, rapid and deep tumor regression was observed in a substantial number of patients when the CTLA-4 inhibitor, ipilimumab, was administered concurrently with nivolumab [<xref ref-type="bibr" rid="CR24">24</xref>]. In this study, 42&#x000a0;% of patients had &#x02265;80&#x000a0;% tumor reduction at 36&#x000a0;weeks, and 1- and 2-year survival rates were 85 and 79&#x000a0;%, respectively. Though the efficacy appeared to be increased as compared with either drug alone, so did the rate of AEs. The observed toxicities were similar to those reported with monotherapy, albeit with higher incidence, including 62&#x000a0;% of patients experiencing grade 3/4 AEs. Other anti-CTLA-4 plus anti-PD-1 trials are ongoing, as are trials exploring dual blockade of the PD-1 pathway (anti-PD-1 plus anti-PD-L1) [<xref ref-type="bibr" rid="CR16">16</xref>]. Additional trials that are planned or have already entered the clinic include combinations of PD-1 pathway inhibitors with LAG-3, indolamine 2,3-dioxygenase 1 (IDO1), sipuleucel-T, or other vaccinations. Immune checkpoint inhibitor combinations with T-cell agonists (i.e., anti-CD40, anti-CD27, and anti-4-1BB) and with other immunostimulants (i.e., IFN, IL-21, and anti-killer immunoglobulin-like receptor [KIR]) are also underway.</p><p>It has been postulated that targeted agents and/or cytotoxic chemotherapy that effectively destroy tumor cells may increase circulating tumor antigens and, therefore, increase the immunogenic response and utility of checkpoint inhibitors [<xref ref-type="bibr" rid="CR35">35</xref>]. In fact, inhibition of mitogen-activated protein kinase with BRAF and/or MEK inhibitors in melanoma cells has been shown to modulate the functions of immune cells in preclinical studies [<xref ref-type="bibr" rid="CR66">66</xref>]. While a phase I/II study (NCT01400451) evaluating the safety and efficacy of combining vemurafenib with ipilimumab recently closed due to hepatic toxicity, a phase II study of vemurafenib followed by sequential ipilimumab in patients with V600 BRAF-mutated melanoma is still ongoing. Initial reports from phase I trials combining nivolumab with vascular endothelial growth factor (VEGF)-targeted therapies (sunitinib or pazopanib) are currently under study to determine the best dose and schedule [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. A combination regimen of pidilizumab (3&#x000a0;mg/kg) plus rituximab (375&#x000a0;mg/m<sup>2</sup>) has also been investigated in a phase II trial in patients with relapsed follicular lymphoma. Of 29 patients evaluable for efficacy, 19 had an objective response (66&#x000a0;%), 15 had a complete response (52&#x000a0;%), and four had a partial response (14&#x000a0;%) [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p>Trials using ipilimumab combined with various cytotoxic chemotherapies, such as temozolomide plus doxycycline (NCT01590082) or fotemustine (NCT01654692) are underway in patients with metastatic melanoma, as are numerous trials of PD-1 pathway inhibitors plus chemotherapy or targeted agents [<xref ref-type="bibr" rid="CR16">16</xref>]. Trials evaluating ipilimumab plus paclitaxel/carboplatin (NCT01165216) and pembrolizumab or nivolumab plus chemotherapy or targeted agents (NCT02039674; NCT01454102) have been started in patients with NSCLC. Details on ongoing phase II and III trials investigating combination regimens with immune checkpoint inhibitors are provided in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec25" sec-type="conclusions"><title>Conclusion</title><p>A better understanding of tumor immunology and immunotherapy, both at the bench and at the bedside, has led to a new and promising area of basic and clinical cancer research. Inhibitors of immune checkpoint regulators have in some cases led to deep and durable responses in patients with advanced malignancies. Many of the observed side effects are manageable and reversible following standard protocols.</p><p>Lessons learned from CTLA-4 and PD-1 blockade, in both the laboratory and the clinic, not only provide the foundation for a future era of superior immune checkpoint inhibition, but also provide a nidus of questions that remain unanswered. Furthering Virchow&#x02019;s initial observation and our understanding of the link between the immune system and malignancy, immune checkpoint inhibitors appear to offer new hope for cancer patients.</p></sec></body><back><fn-group><fn><p>This article is part of the topical collection on Immuno-Oncology.</p></fn></fn-group><ack><p>The authors take full responsibility for the content of this publication and confirm that it reflects their viewpoint and expertise. Professional medical writing assistance was provided by Britt Anderson, Ph.D., and professional editing assistance was provided by Karin McGlynn at StemScientific and was funded by Bristol-Myers Squibb. Neither Bristol-Myers Squibb nor StemScientific influenced the content of the manuscript, nor did the author receive financial compensation for authoring the manuscript.</p><p>The manuscript does not contain original clinical studies or patient data that have not been published or presented elsewhere.</p><p>Drs. Shih, Arkenau, and Infante have no conflicts of interest to declare.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balkwill</surname><given-names>F</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Inflammation and cancer: back to Virchow?</article-title><source>Lancet</source><year>2001</year><volume>357</volume><issue>9255</issue><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04046-0</pub-id><pub-id pub-id-type="pmid">11229684</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bour-Jordan</surname><given-names>H</given-names></name><name><surname>Esensten</surname><given-names>JH</given-names></name><name><surname>Martinez-Llordella</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family</article-title><source>Immunol Rev</source><year>2011</year><volume>241</volume><issue>1</issue><fpage>180</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01011.x</pub-id><pub-id pub-id-type="pmid">21488898</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><issue>4</issue><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmid">22437870</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>O&#x02019;Day</surname><given-names>SJ</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>8</issue><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1003466</pub-id><pub-id pub-id-type="pmid">20525992</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><etal/></person-group><article-title>Ipilimumab plus dacarbazine for previously untreated metastatic melanoma</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>26</issue><fpage>2517</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1104621</pub-id><pub-id pub-id-type="pmid">21639810</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Lorigan</surname><given-names>P</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name><etal/></person-group><article-title>Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><issue>3</issue><fpage>1042</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-2033</pub-id><pub-id pub-id-type="pmid">20086001</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014;32(18 suppl):abstr LBA9000. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/133842-144">http://meetinglibrary.asco.org/content/133842-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>26</issue><fpage>2443</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200690</pub-id><pub-id pub-id-type="pmid">22658127</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armand</surname><given-names>P</given-names></name><name><surname>Nagler</surname><given-names>A</given-names></name><name><surname>Weller</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>33</issue><fpage>4199</fpage><lpage>4206</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.48.3685</pub-id><pub-id pub-id-type="pmid">24127452</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Smothers JF, Hoos A, Langermann S, et al. AMP-224, a fusion protein that targets PD-1. Ann Oncol. 2013;24(1 suppl):abstr L02.04. <ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/content/24/suppl_1/i7.6.full">http://annonc.oxfordjournals.org/content/24/suppl_1/i7.6.full</ext-link>. Accessed 3 March 2014.</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Cho D, Sosman J, Sznol M, et al. Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2013;31(15 suppl):abstr 4505. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/115491-132">http://meetinglibrary.asco.org/content/115491-132</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol. 2014;32(15 suppl):abstr 5011. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/128960-144">http://meetinglibrary.asco.org/content/128960-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Tykodi</surname><given-names>SS</given-names></name><name><surname>Chow</surname><given-names>LQ</given-names></name><etal/></person-group><article-title>Safety and activity of anti-PD-L1 antibody in patients with advanced cancer</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>26</issue><fpage>2455</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200694</pub-id><pub-id pub-id-type="pmid">22658128</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Segal NH, Antonia SJ, Brahmer JR, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol. 2014;32(15 suppl):abstr 3002. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/134136-144">http://meetinglibrary.asco.org/content/134136-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang-Gillam</surname><given-names>A</given-names></name><name><surname>Plambeck-Suess</surname><given-names>S</given-names></name><name><surname>Goedegebuure</surname><given-names>P</given-names></name><etal/></person-group><article-title>A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma</article-title><source>Invest New Drugs</source><year>2013</year><volume>31</volume><issue>3</issue><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1007/s10637-012-9866-y</pub-id><pub-id pub-id-type="pmid">22864469</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">ClinicalTrials.gov. 2014. <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">http://clinicaltrials.gov</ext-link>. Accessed 7 July 2014.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>ED</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><etal/></person-group><article-title>Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>7</issue><fpage>700</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70189-5</pub-id><pub-id pub-id-type="pmid">24831977</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Luft</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>17</issue><fpage>2046</fpage><lpage>2054</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.38.4032</pub-id><pub-id pub-id-type="pmid">22547592</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally, advanced, unresectable melanoma. In: Presented at ESMO 2013. Abstract 24LBA. <ext-link ext-link-type="uri" xlink:href="http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx%23">http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx#</ext-link>. Accessed 3 March 2014.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Yervoy<sup>&#x000ae;</sup> (ipilimumab) prescribing information. Bristol-Myers Squibb Company, Princeton. 2013.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Kefford</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>5</issue><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.44.6112</pub-id><pub-id pub-id-type="pmid">23295794</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-na&#x000ef;ve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial. J Clin Oncol. 2014;32(15 suppl):abstr 9002. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/125578-144">http://meetinglibrary.asco.org/content/125578-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Atkins MB, Kudchadkar RR, Sznol M, et al. Pidilizumab in metastatic melanoma: results from a multicenter phase II, open-label, randomized trial. J Clin Oncol. 2014;32(15 suppl):abstr 9001. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/131463-144">http://meetinglibrary.asco.org/content/131463-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Sznol M, Kluger H, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 2014;32(15 suppl):abstr LBA9003. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/126008-144">http://meetinglibrary.asco.org/content/126008-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Garon EB, Balmanoukian A, Hamid O, et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). WCLC. 2013. Abstract MO18.02. <ext-link ext-link-type="uri" xlink:href="https://www.webges.com/cview/library/wclc/home">https://www.webges.com/cview/library/wclc/home</ext-link>. Accessed 3 March 2014.</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15 suppl):abstr 8020. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/133339-144">http://meetinglibrary.asco.org/content/133339-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15 suppl):abstr 8007. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/132675-144">http://meetinglibrary.asco.org/content/132675-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Brahmer J, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. J Clin Oncol. 2014;32(15 suppl):abstr 8112. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/125774-144">http://meetinglibrary.asco.org/content/125774-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Gettinger S, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy and correlation of outcomes with PD-L1 status. J Clin Oncol. 2014;32(15 suppl):abstr 8024. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/125774-144">http://meetinglibrary.asco.org/content/125774-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><etal/></person-group><article-title>Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><issue>6</issue><fpage>552</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70093-7</pub-id><pub-id pub-id-type="pmid">23598172</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Vogelzang</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>3</issue><fpage>286</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70030-0</pub-id><pub-id pub-id-type="pmid">24556040</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Esteban</surname><given-names>E</given-names></name><etal/></person-group><article-title>Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><issue>8</issue><fpage>760</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.50.3961</pub-id><pub-id pub-id-type="pmid">24297950</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Motzer R, Rini B, McDermott D, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. J Clin Oncol. 2014;32(15 suppl):abstr 5009. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/125893-144">http://meetinglibrary.asco.org/content/125893-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol. 2014;32(18 suppl):abstr LBA9008. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/130118-144">http://meetinglibrary.asco.org/content/130118-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Immunological aspects of cancer chemotherapy</article-title><source>Nat Rev Immunol</source><year>2008</year><volume>8</volume><issue>1</issue><fpage>59</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/nri2216</pub-id><pub-id pub-id-type="pmid">18097448</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Calabr&#x000f2; L, Morra A, Fonsatti E, et al. A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. J Clin Oncol. 2014;32(15 suppl):abstr 7531. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/129923-144">http://meetinglibrary.asco.org/content/129923-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fecher</surname><given-names>LA</given-names></name><name><surname>Agarwala</surname><given-names>SS</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><etal/></person-group><article-title>Ipilimumab and its toxicities: a multidisciplinary approach</article-title><source>Oncologist</source><year>2013</year><volume>18</volume><issue>6</issue><fpage>733</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2012-0483</pub-id><pub-id pub-id-type="pmid">23774827</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><issue>10</issue><fpage>1020</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.53.0105</pub-id><pub-id pub-id-type="pmid">24590637</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Horn L, Herbst RS, Spigel D, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). WCLC. 2013. Abstract MO18.01. <ext-link ext-link-type="uri" xlink:href="https://www.webges.com/cview/library/wclc/home">https://www.webges.com/cview/library/wclc/home</ext-link>. Accessed 3 March 2014.</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabr&#x000f2;</surname><given-names>L</given-names></name><name><surname>Morra</surname><given-names>A</given-names></name><name><surname>Fonsatti</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><issue>11</issue><fpage>1104</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70381-4</pub-id><pub-id pub-id-type="pmid">24035405</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>KE</given-names></name><name><surname>Blansfield</surname><given-names>JA</given-names></name><name><surname>Tran</surname><given-names>KQ</given-names></name><etal/></person-group><article-title>Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>15</issue><fpage>2283</fpage><lpage>2289</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.04.5716</pub-id><pub-id pub-id-type="pmid">16710025</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>K&#x000e4;hler</surname><given-names>KC</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name></person-group><article-title>Management of immune-related adverse events and kinetics of response with ipilimumab</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>21</issue><fpage>2691</fpage><lpage>2697</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.41.6750</pub-id><pub-id pub-id-type="pmid">22614989</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attia</surname><given-names>P</given-names></name><name><surname>Phan</surname><given-names>GQ</given-names></name><name><surname>Maker</surname><given-names>AV</given-names></name><etal/></person-group><article-title>Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>25</issue><fpage>6043</fpage><lpage>6053</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.06.205</pub-id><pub-id pub-id-type="pmid">16087944</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Inhibitory B7-family molecules in the tumour microenvironment</article-title><source>Nat Rev Immunol</source><year>2008</year><volume>8</volume><issue>6</issue><fpage>467</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/nri2326</pub-id><pub-id pub-id-type="pmid">18500231</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>F</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><etal/></person-group><article-title>Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><issue>3</issue><fpage>1089</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">15705911</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Hoos</surname><given-names>A</given-names></name><name><surname>O&#x02019;Day</surname><given-names>S</given-names></name><etal/></person-group><article-title>Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><issue>23</issue><fpage>7412</fpage><lpage>7420</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1624</pub-id><pub-id pub-id-type="pmid">19934295</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol. 2014;32(15 suppl):abstr 6011. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/132361-144">http://meetinglibrary.asco.org/content/132361-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Antonia SJ, Brahmer JR, Gettinger S, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15 suppl):abstr 8113. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/125962-144">http://meetinglibrary.asco.org/content/125962-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Antonia SJ, Gettinger S, Chow LQ, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol. 2014;32(15 suppl):abstr 8023. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/125736-144">http://meetinglibrary.asco.org/content/125736-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Rizvi NA, Chow LQ, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol. 2014;32(15 suppl):abstr 8022. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/125751-144">http://meetinglibrary.asco.org/content/125751-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>R</given-names></name><name><surname>Rotem-Yehudar</surname><given-names>R</given-names></name><name><surname>Slama</surname><given-names>G</given-names></name><etal/></person-group><article-title>Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><issue>10</issue><fpage>3044</fpage><lpage>3051</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4079</pub-id><pub-id pub-id-type="pmid">18483370</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armand</surname><given-names>P</given-names></name><name><surname>Welch</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><etal/></person-group><article-title>Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era</article-title><source>Br J Haematol</source><year>2013</year><volume>160</volume><issue>5</issue><fpage>608</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1111/bjh.12176</pub-id><pub-id pub-id-type="pmid">23278720</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Infante JR, Powderly JD, Burris HA, et al. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. J Clin Oncol. 2013;31(15 suppl):abstr 3044. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/117257-132">http://meetinglibrary.asco.org/content/117257-132</ext-link>. Accessed 17 April 2014.</mixed-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Kudchadkar</surname><given-names>RR</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>34</issue><fpage>4311</fpage><lpage>4318</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.51.4802</pub-id><pub-id pub-id-type="pmid">24145345</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Hamid O, Robert C, Ribas A, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). J Clin Oncol. 2014;32(15 suppl):abstr 3000. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/134788-144">http://meetinglibrary.asco.org/content/134788-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Kefford R, Ribas A, Hamid O, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;32(15 suppl):abstr 3005. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/130007-144">http://meetinglibrary.asco.org/content/130007-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Gandhi L, Balmanoukian A, Hui R, et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression. In: Presented at the American Association for Cancer Research (AACR) annual meeting 2014, 5&#x02013;9 April 2014, San Diego. Abstract CT105. <ext-link ext-link-type="uri" xlink:href="http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1a1f4fbb-a45d-407f-861e-75f8d79db782&#x00026;cKey=875f683f-04fe-450a-a9cb-f51cac5436b8&#x00026;mKey=6ffe1446-a164-476a-92e7-c26446874d93">http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1a1f4fbb-a45d-407f-861e-75f8d79db782&#x00026;cKey=875f683f-04fe-450a-a9cb-f51cac5436b8&#x00026;mKey=6ffe1446-a164-476a-92e7-c26446874d93</ext-link>. Accessed 17 April 2014.</mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Choueiri TK, Fishman MN, Escudier B et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. J Clin Oncol. 2014;32(15 suppl):abstr 5012. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/125914-144">http://meetinglibrary.asco.org/content/125914-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Powderly JD, Koeppen H, Hodi FS, et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J Clin Oncol. 2013;31(15 suppl):abstr 3001. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/112657-132">http://meetinglibrary.asco.org/content/112657-132</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisielow</surname><given-names>M</given-names></name><name><surname>Kisielow</surname><given-names>J</given-names></name><name><surname>Capoferri-Sollami</surname><given-names>G</given-names></name><etal/></person-group><article-title>Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells</article-title><source>Eur J Immunol</source><year>2005</year><volume>35</volume><issue>7</issue><fpage>2081</fpage><lpage>2088</lpage><pub-id pub-id-type="doi">10.1002/eji.200526090</pub-id><pub-id pub-id-type="pmid">15971272</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngiow</surname><given-names>SF</given-names></name><name><surname>Teng</surname><given-names>MW</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Prospects for TIM3-targeted antitumor immunotherapy</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><issue>21</issue><fpage>6567</fpage><lpage>6571</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1487</pub-id><pub-id pub-id-type="pmid">22009533</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Schubart</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><issue>12</issue><fpage>1245</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1038/ni1271</pub-id><pub-id pub-id-type="pmid">16286920</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatos</surname><given-names>CA</given-names></name><name><surname>Chakravarti</surname><given-names>S</given-names></name><name><surname>Cha</surname><given-names>E</given-names></name><etal/></person-group><article-title>Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance</article-title><source>Nat Immunol</source><year>2003</year><volume>4</volume><issue>11</issue><fpage>1102</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1038/ni988</pub-id><pub-id pub-id-type="pmid">14556006</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nocentini</surname><given-names>G</given-names></name><name><surname>Ronchetti</surname><given-names>S</given-names></name><name><surname>Petrillo</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Pharmacological modulation of GITRL/GITR system: therapeutic perspectives</article-title><source>Br J Pharmacol</source><year>2012</year><volume>165</volume><issue>7</issue><fpage>2089</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01753.x</pub-id><pub-id pub-id-type="pmid">22029729</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boczkowski</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Pruitt</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy</article-title><source>Cancer Gene Ther</source><year>2009</year><volume>16</volume><issue>12</issue><fpage>900</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1038/cgt.2009.39</pub-id><pub-id pub-id-type="pmid">19498460</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vella</surname><given-names>LJ</given-names></name><name><surname>Pasam</surname><given-names>A</given-names></name><name><surname>Dimopoulos</surname><given-names>N</given-names></name><etal/></person-group><article-title>MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells</article-title><source>Cancer Immunol Res</source><year>2014</year><volume>2</volume><issue>4</issue><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0181</pub-id><pub-id pub-id-type="pmid">24764582</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="other">Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(15 suppl):abstr 5010. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/125881-144">http://meetinglibrary.asco.org/content/125881-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR68"><label>68.</label><mixed-citation publication-type="other">Hammers H, Plimack ER, Infante JR, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(15 suppl):abstr 4504. <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/129458-144">http://meetinglibrary.asco.org/content/129458-144</ext-link>. Accessed 1 July 2014.</mixed-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westin</surname><given-names>JR</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>1</issue><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70551-5</pub-id><pub-id pub-id-type="pmid">24332512</pub-id></element-citation></ref></ref-list></back></article>